!"#$"%&! " " #kL MLL1I NGCCUkSLS:CC1C8L82326,2013CLNI NGLLC1UkLANDAWAkDS:CC1C8L826, 2013SCI LN1I II CSLSSI CNS:CC1C8L82630,2013IMCk1AN1 LCCA1ICNSACk Cmce. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23A, 1e|ephone: (619) S2S-6200Auendee Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllon8us|ness Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pall u LobbyCareer Connecnon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall l-C, ulscovery CenLer - 8ooLh 1421Ch||d Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Call for Locauon, 1e|ephone: (8S8) 2S4-2S63C||n|ca| 1r|a|s osters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllon Coat]8aggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . under Pall u LscalaLorConc|erge Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllonD|scovery Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall l-C, 8ooLh 1421Lxh|b|t na|| . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall l-CI|rst A|d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8ox Cmce C Ioundanon 8ooth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall l-C, ulscovery CenLer - 8ooLh 1421Ioundanon Donors' Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . 248-CGramn Wa||s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllon and LxhlblL Pall l-C note| keservanons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllonIndustry-Supported Sympos|a Informanon . . . . . . . . . . . . . . Pall u LobbyInnovanon 1heater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall l-C, 8ooLh 731Lost and Iound. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . AC8 Cmce (23A)Membersh|p 8ooth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllonNewsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26A-8, 1e|ephone: (619) S2S-6204Nurs|ng Mothers' koom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7ACverow kooms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .238 (San ulego Convenuon CenLer) 308 (PllLon San ulego 8ayfronL CenLer)oster na||. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall 82-C-urayer koom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21kecharge Areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .LxhlblL Pall l-C,Auendee Lounge (Salls avlllon) keg|stranon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salls avlllonkestaurant keservanons. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pall 8 Lobby and Salls avlllonk|bbon D|str|bunon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8eglsLrauon (Salls avlllon)!"##$%&!"'"() Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pall u Lobby (Monday - Wednesday)Shuu|e 8us . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pall L Lobby S|mp|e 1asks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Palls l-C, ulscovery CenLer - 8ooLh 1421Speaker keady koom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221echno|ogy Center (CML]Internet) . . . . . . . . . . . . . . . . . . . . . Salls avlllonV|s|tor Informanon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pall 8 LobbyWhee|cha|rs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Crder Lhrough ScooLAround, lnc.,1e|ephone: (888) 441-7S7S. (1he San ulego Convenuon CenLer does noL provldewheelchalrs for general use.)W|-I| Way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LxhlblL Pall l-CSpec|a| Needs lf you requlre speclal arrangemenLs, please conLacL Lhe AC8 Cmce (23A), 1e|ephone: (619) S2S-6200.Lmergency Contact Informanon Space ls provlded on Lhe back of your badge Lo llsL name and Lelephone numbers of your emergencyconLacLs. lease compleLe Lhls lnformauon before lnserung your badge ln your badge holder.KJob Number: 20117Revision No: 1Date: 8/6/13Y M C051_36588 Pg 3IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONSPatients treated with ENBREL (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown.Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.Pediatric PatientsIn patients who initiated therapy at 18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkins and non-Hodgkins lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.NEUROLOGIC EVENTSTreatment with TNF-blocking agents, including ENBREL, has been associated with rare (= 18 years of age.We conducLed a maLched cohorL analysls among pauenLs sausfylng aL leasL one of Lhe followlng crlLerla: a) dlagnosls of SSc on aL leasL Lwo vlslLs wlLhln a Lwo-year perlod beLween !an 1996 and uec 2010 by a non-rheumaLologlsL physlclan, b) dlagnosls of SSc on aL leasL one vlslL by a rheumaLologlsL or from a hosplLal. 1o lncrease speclclLy we excluded cases LhaL were noL conrmed by a rheumaLologlsL lf Lhey were seen aL a laLer polnL. 1en conLrols maLched by blrLh year, sex and calendar year of follow-up were selecLed from Lhe general populauon for each case. newly recorded Ml evenLs from hosplLal or deaLh cerucaLe were recorded as an ouLcome. We esumaLed relauve rlsks (88s) comparlng SSc wlLh age-, sex- and enLry ume-maLched comparlson cohorLs, ad[usung for poLenual cardlovascular rlsk facLors.kesu|ts: Among 1,208 lndlvlduals wlLh lncldenL SSc (84 female, mean age of 36 yrs [Su 13.0]), 90 developed Ml (lncldence raLe= 20.2 per 1000 person years) (1able 1). Compared wlLh non-SSc lndlvlduals (n= 12,080), Lhe age-, sex-, and enLry-ume-maLched 88 for Ml was 3.8 (93 Cl, 2.9 Lo 4.8). 1he rlsk was 9 umes greaLer wlLhln Lhe rsL year aer Lhe dlsease onseL and progresslvely decreases over ume. Aer furLher ad[usLmenL for anglna, CCu, obeslLy, cardlovascular dlsease, dlabeLes, hormone replacemenL Lherapy, dysllpldemla, non sLeroldal anu-lnammaLory drugs, Cox-2 lnhlblLors, number of hosplLallzauons and Charlson's comorbldlLy lndex aL basellne, Lhe 88 remalned slmllar (4.0, 93 Cl, 3.1 Lo 3.3). 1hese resulLs perslsLed among men, women and dlerenL age groups (1able 1).Conc|us|on: 1hls large populauon-based sLudy lndlcaLes an lncreased rlsk of Ml ln pauenLs wlLh SSc, especlally wlLhln Lhe rsL year of dlsease dlagnosls.1hese ndlngs supporL lncreased monlLorlng of Ml compllcauon and rlsk facLors ln Lhose wlLh SSc, parucularly durlng Lhe early phase of SSc dlagnosls.Incidence Rate Ratios of MISSc(n = 1,208)Non-SSc (n = 12,080)Cases, N 90 281Incidence Rate/1000 Person-Years 20.2 5.3Age-sex-entry time matched RRs (95% CI) 3.8 (2.9 4.8) 1.0Multivariable RRs (95% CI) 4.0 (3.1 5.3) 1.0Disease Duration< 1 year9.0 (5.8 13.9) 1.01-4.9 years 3.0 (2.0 4.4) 1.05+ years 1.6 (0.8 3.1) 1.0Female 4.1 (3.0 5.6) 1.0Male 4.2 (2.2 7.9) 1.0Age Group< 45 3.0 (0.7 14.1) 1.045 - 59 5.2 (2.9 9.4) 1.060-74 3.5 (2.3 5.2) 1.075 + 5.4 (3.2 9.3) 1.01ab|e 1.8elauve rlsk of lncldenL Ml accordlng Lo SysLemlc Sclerosls sLaLus.D|sc|osures: l. Pemmau, none.noou764. Inammatory D|sease Due to Dysregu|ated Nuc|ear Iactor-x8 Acnvanon and Impa|red 1ype I Interferon kesponse kesu|nng Irom a De Novo numan NLMC nypomorph|c MutanonAlex Wessel and Lr|c nanson, nauonal lnsuLuLe of ArLhrlus and MusculoskeleLal and Skln ulseases, nauonal lnsuLuLes of PealLh, 8eLhesda, Mu8ackground]urpose: 1he nl-k8 famlly of Lranscrlpuon facLors regulaLe lnnaLe and adapuve lmmunlLy, ln addluon Lo drlvlng pro-lnammaLory-dlsease sLaLes.1he Lype l lnLerferon response acLs ln parallel, and ls medlaLed by l8l3 and l8l7 Lranscrlpuon facLors.1he l8ls are Lrlggered by Lhe 8lC-l-llke famlly of recepLors (8L8s) ln broblasLs and 1oll-llke recepLors (1L8s) ln dendrluc cells and macrophages.8oLh nl-k8 acuvauon and Lhe 1ype l lln response requlre Lhe nl-k8 essenual modulaLor (nLMC) for normal funcuon. 1he mechanlsms by whlch nLMC ls regulaLed Lo lnLegraLe varlous upsLream slgnals Lo dlrecL Lranscrlpuon ln anuvlral lmmune defense and lnammaLory dlsease ls unknown. We presenL Lhe molecular mechanlsm by whlch a naLurally occurrlng nLMC muLauon assoclaLed wlLh lnammaLory dlsease leads Lo aberranL cell responses. Methods: Cenomlc unA and cunA from dermal broblasLs and perlpheral blood cells from a pauenL wlLh opuc neurlus, pannlcullus and physlcal characLerlsucs conslsLenL wlLh nLMC SUNDAOCTOBER 27, 2013!"#$ &'()'*+ ,((- 40- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoomuLauon were analyzed Lo deLermlne Lhe genoLype and eecL on nLMC proLeln producL.auenL cells were sumulaLed wlLh 1nl, anu-Cu3/Cu28,vlral nuclelc acld analogs, and 8Sv and Plv3 lnfecuon.Cene expresslon prollng, cyLoklne producuon and blochemlcal analysls was performed Lo characLerlze and deLermlne Lhe mechanlsm of aberranL slgnallng produced by Lhe muLanL form of nLMC. kesu|ts: We ldenued an lndlvldual wlLh LcLodermal uysplasla, a hlsLory of ln uLero cyLomegalovlrus exposure, and perslsLenL lnammaLory dlsease.Sanger sequenclng revealed a de novo synonymous muLauon ln lk8kC, whlch encodes nLMC, Lhe nl-k8 essenual modulaLor.1he muLauon resulLs ln an m8nA spllclng defecL whlch leads Lo Lhe producuon of a muLanL proLeln conLalnlng an ln-frame deleuon of 31 resldues, lacklng a prevlously ldenued 1Ank (18Al famlly member-assoclaLed nlk8 acuvaLor) lnLeracuon domaln.Co-lmmunopreclplLauon sLudles revealed LhaL Lhe muLanL form of nLMC from pauenL 1 cells ls unable Lo recrulL Lhe l8l3 klnase 1Ank-blndlng klnase-1 (18k1), due Lo lmpalred assoclauon wlLh 1Ank. auenL broblasLs sumulaLed wlLh Lhe 8L8 llgand poly(l:C) led Lo lmpalred lnducuon of l8l3 response genes llN81, ccl5, c\cl10, ll10, OA5l, and uu\58.ConsequenLly, dermal broblasLs lnfecLed wlLh 8Sv or hlv3 demonsLraLed lncreased vlrus propagauon relauve Lo healLhy conLrol cells. lmpalred gene expresslon occurred desplLe enhanced nuclear Lranslocauon of l8l3, suggesung LhaL Lhe mechanlsm of lmpalred acuvauon ls noL a slmple defecL ln nuclear locallzauon of Lhe Lranscrlpuon facLor. ln conLrasL Lo Lhe lmpalred Lype l lln response, canonlcal lkk acuvauon and gene lnducuon ln dermal broblasLs appeared relauvely normal followlng 1nl LreaLmenL.Conc|us|on: 1hese resulLs lllusLraLe a novel mechanlsm of auLolnammaLory dlsease due Lo aberranL expresslon of an alLernaLely spllced nLMC and declenL l8l3-medlaLed response.D|sc|osures: A. Wesse|, none, L. nanson, none.1213 ru76S. Ang|ogen|c Iactor Dysregu|anon and k|sk of Adverse regnancy Cutcome |n Lupus regnanc|esIane L. Sa|mon, PosplLal for Speclal Surgery, new ?ork, n?8ackground]urpose: regnanL women wlLh lupus and AL are aL lncreased rlsk for adverse ouLcomes, parucularly preeclampsla (L), yeL ldenucauon of Lhose desuned for compllcauons remalns eluslve. uysregulauon of anglogenlc facLors conLrlbuLes Lo paLhogenesls of placenLal lnsumclency and preeclampsla. lacenLally derlved sllL1 anLagonlzes proanglogenlc proLelns (placenLal growLh facLor, lCl, vLCl) whlch are necessary for developmenL of Lhe placenLa and for vascular homeosLasls. We prospecuvely sLudled pauenLs Lo deLermlne wheLher levels of anglogenlc facLors early ln pregnancy would predlcL ouLcomes. Methods: 1he 8CMlSSL SLudy (1redlcLors of pkegnancy "uLcome: 8lo,arkers -n anuphosphollpld anubody Syndrome and SysLemlc +upus )ryLhemaLosus) enrolled 384 pregnanL women wlLh >4 AC8 SLL crlLerla and/or AL and 133 healLhy pregnanL conLrols (PC). Sub[ecLs were evaluaLed and blood collecLed monLhly beglnnlng aL 20mg/d, proLelnurla >1gm/24hr, and creaunlne >1.2 mg/dL. oor pregnancy ouLcomes (CC) were dened as preeclampsla, feLal deaLh, neonaLal deaLh, preLerm dellvery 70) of progresslng Lo perslsLenL arLhrlus, based on Lhe predlcuon model of vlsser. 1he vlsser algorlLhm and 2010 crlLerla for 8A have slmllar dlscrlmlnauve ablllues Lo ldenufy pauenLs aL rlsk of perslsLenL arLhrlus aL 1 year. auenLs were randomlzed lnLo 3 lnducuon Lherapy sLraLegles: (A) Lrlple uMA8u Lherapy (M1x 23 mg + sulfasalazlne (SAS) 2 gr. + hydroxychloroqulne (PCC)) 400 mg wlLh lm CCs (uepomedrol 120mg), (8) Lrlple uMA8u Lherapy wlLh an oral CCs Laperlng scheme (sLarung 13 mg) and (C) M1x wlLh oral CCs slmllar Lo 8. 1reaLmenL sLraLegles were 'ughLly conLrolled', wlLh pauenLs belng examlned every 3 monLhs and LreaLmenL declslons based upon Lhe orlglnal uAS Lhresholds for low dlsease acuvlLy. We lnvesugaLed followlng response parameLers over ume: uAS, PAC, uslng Lhe area under Lhe curve (AuC). We also looked aL radlographlc progresslon aer 12 monLhs of Lherapy, medlcauon usage and adverse evenLs.kesu|ts: A LoLal of 281 pauenLs were lncluded ln Lhe hlgh probablllLy sLraLum and randomly asslgned Lo (A) (n=91), (8) (n=93) or (C) (n=97).auenLs were mosLly females (68) wlLh an average sympLom durauon of 166 days (93 Cl: 136 - 177). AL basellne 267 (93) of pauenLs fullled Lhe 2010 crlLerla for 8A,216 (77) pauenLs were ACA posluve and 48 (16) pauenLs had eroslons. Cver ume dlsease acuvlLy and funcuonal ablllLy were respecuvely-2-39 (-4-77 Lo -0-00, 93Cl) and -1-67 (-3-33 Lo 0-02, 93Cl)lower ln pauenLs wlLh Lrlple uMA8u Lherapy compared wlLh M1x mono-Lherapy. Aer 3 monLhs, less LreaLmenL fallure occurred ln Lhe Lrlple uMA8u Lherapy groups, resulung ln Lhe prescrlpuon of 30 fewer blologlcals. 1hls dlerence remalned over ume. no dlerences MCNDAOCTOBER 28, 2013!"#$ &'()'*+ ,((- 74- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoowere seen beLween boLh CC brldglng Lheraples. 8especuvely 13, 30, and 18 of pauenLs ln arm A, 8, and C had radlographlc progresslon aer 1 year. no dlerences ln serlous adverse evenLs were seen.Conc|us|on: ln pauenLs wlLh early 8A Lrlple uMA8u Lherapy ls superlor Lo M1x mono-Lherapy even aer 12 monLhs of Lherapy. lurLhermore boLh lnLramuscular and oral CCs can be used as brldglng Lherapy.D|sc|osures: . n. . de Iong, none.noou1694. A kandom|sed 1r|a| of a 8race for ate||ofemora| Csteoarthr|ns 1argenng knee a|n and 8one Marrow Les|onsDav|d 1. Ie|son, unlverslLy of ManchesLer, ManchesLer, unlLed klngdom8ackground]urpose: aLellofemoral (l) braces have been shown Lo lncrease conLracL area ln Lhls [olnL, decreaslng focal sLress and may also correcL paLellar malallgnmenL. 8one marrow leslons (8MLs) are leslons ln Lhe subchondral bone of osLeoarLhrlus (CA) knees on M8l LhaL are caused ln parL by focal sLress ln Lhe [olnL.8ecause 8ML slze correlaLes wlLh knee paln severlLy, because Lhey predlcL sLrucLural progresslon and because recenL evldence suggesLs, unllke carulage, LhaL Lhelr volumes ucLuaLe subsLanually ln as llule as 6 weeks, 8ML's may be a good ouLcome Lo LesL shorL Lerm sLrucLure modlcauon ln CA Lrlals. We performed a Lrlal Lesung Lhe emcacy of Lhe 8lCSkln paLellar Lracklng C brace (Cssur, lnc). Methods: Lllglble sub[ecLs had Lo have paln dally of >=40/100 for Lhe lasL 3 monLhs durlng a l acuvlLy and on examlnauon had Lenderness over paLellar faceL or a posluve paLellar compresslon LesL.x-rays had Lo show kL grade 2 or 3 lCA whlch was worse Lhan ublofemoral dlsease. AL basellne, sub[ecLs were randomly allocaLed Lo lmmedlaLe or 6 weeks provlslon of Lhe brace, Lhe Lrlal lasLed 6 weeks.Sub[ecLs wlLh oLher forms of arLhrlus were excluded as were Lhose lnellglble for M8ls or wlLh lmpalred renal funcuon. Cadollnlum M8ls were acqulred on a 1.3 1 M8l aL basellne, and aL 6 weeks.osLgadollnlum faL suppressed saglual and u welghLed axlal lmages were used for 8ML's whlch were manually segmenLed (bllnded Lo sequence and Lo LreaLmenL) aL all ume polnLs. 1he prlmary sympLom ouLcome was Lhe change ln paln aL 6 weeks (0 - 100 vAS scale) durlng Lhe l palnful acuvlLy ln Lhe more sympLomauc knee and Lhe prlmary sLrucLural ouLcome was 8ML volume ln Lhe l [olnL of LhaL knee (paLella and Lrochlea). We also examlned ublofemoral (1l) 8ML volumes as a conLrol unLreaLed reglon.Analyses used muluple llnear regresslon wlLh an l11 approach. kesu|ts: We randomlsed 126 sub[ecLs age 40-70 years (mean age 33.3 years (Su 7.3 years), 72 females (37.1).Mean paln score aL basellne was 64.6. nlneLy of Lhe 123 wlLh M8l scans (72) had l 8ML's aL basellne. Sub[ecLs wore Lhe brace for a mean of 7.4 hrs/day. Slx sub[ecLs wlLhdrew durlng Lhe 8C1 (an addluonal 2 dld noL auend one sesslon, and Lherefore had only one M8l). Compared wlLh Lhe conLrol group, Lhe brace group had boLh a slgnlcanL reducuon ln l-relaLed knee paln and a decrease ln Lhe volume of 8ML's ln Lhe l buL noL ln Lhe 1l [olnL (see 1able). Conc|us|on: A paLellofemoral brace ls emcaclous for LreaLmenL of l CA reduclng boLh sympLoms and 8ML volumes ln Lhe LargeLed comparLmenL. 8ML's may be a responslve ouLcome measure ln CA Lrlals. RANDOMISED TRIAL RESULTSVariable NO BRACE GROUP BRACE GROUPBetween Groups DifferenceChange@ 6 weeks In:Mean change(95% CI)Mean change(95% CI)Mean difference in change (95% CI)pPRIMARY Symptom OUTCOME: NominatedVAS (0 100)-1.29(-6.39, 3.80)-18.16(-23.88, -12.44)16.87(9.30, 24.43)3 S!C and >3 1!C, C8>0.3mg/dL [uLn 1.0 mg/dL]) desplLe uMA8u and/or nSAlu Lherapy (SuMMl1 1, n=613, SuMMl1 2, n=132) or prevlously LreaLed wlLh uMA8u and/or nSAlu, and prlor anu-1nlo Lherapy (SuMMl1 2, n=180) were randomlzed Lo uS143mg, 90mg, or 8C aL wks 0, 4, and q12wks, Lhereaer. AL wk16, pauenLs wlLh 4) ln pauenLs LreaLed wlLh eASCs, lncluded pyrexla (19), headache (13), urlnary LracL lnfecuon (13), upper resplraLory LracL lnfecuon (11), nausea (11), malalse, resplraLory LracL lnfecuon, vomlung and asLhenla (6 each). ln secondary endpolnLs, a clear dose-response eecL was noL observed. Maxlmum cllnlcal beneL ln Lhe l11 populauon was observed ln cohorL A. AC820/30/70 responses were observed ln 43/20/3 of pauenLs ln cohorL A versus 28/14/3 of pauenLs on placebo aL monLh 1. AL monLh 3, AC8 responses were 23/13/3 and 0/0/0 ln cohorL A and placebo respecuvely. 1he uAS 28 good/moderaLe response was 10/33 ln cohorL A and 0/43 ln Lhe placebo group aL monLh 1. 1hese values were 20/20 and 0/0 aL monLh 3 for cohorL A and placebo respecuvely. Conc|us|on: 1hese early cllnlcal resulLs are Lhe rsL Lo suggesL LhaL lv lnfuslon of eASCs ls well LoleraLed along 24 weeks and could be assoclaLed wlLh cllnlcal beneL ln Lhe LreaLmenL of refracLory 8A.D|sc|osures: I. A|varo-Grac|a, none.11:13 tu264S. atho|og|ca| ko|es of the Ann-Cx|danve Lnzyme erox|redox|n 2 |n anents W|th kawasak| D|seasek|e karasawa, lnsuLuLe of Medlcal Sclence, SL. Marlanna unlverslLy School of Medlclne, kawasakl, !apan8ackground]urpose: Anu-endoLhellal cell anubodles (ALCA) are auLoanubodles LhaL are deLecLed frequenLly ln vascullus caused by, for example, kawasakl dlsease (ku). Powever, ALCA LargeL molecules have been poorly ldenued, whlch hampers our undersLandlng of Lhe roles of ALCA. We almed Lo deLecL LargeL proLelns of ALCA comprehenslvely by proLeomlcs and lnvesugaLe Lhelr cllnlcal lmporLance ln pauenLs wlLh ku. Methods: We separaLed proLelns exLracLed from human umblllcal veln endoLhellal cells (PuvLCs) and PeLa cells by 2-dlmenslonal elecLrophoresls and Lransferred Lhem onLo membranes. Anugens LhaL were posluve only ln Lhe PuvLC samples buL noL ln Lhe PeLa cell samples were deLecLed by wesLern bloL, uslng serum samples from pauenLs wlLh vascullus. nexL, we ldenued Lhe deLecLed proLelns by pepude mass nger-prlnung and characLerlzed Lhelr anugenlclLy by preparlng recomblnanL anugens and anubodles Lo Lhem. lurLhermore, we lnvesugaLed Lhe frequency, cllnlcal slgnlcance, and paLhologlcal roles of ALCA agalnsL lndlvldual ldenued LargeL auLoanugens. kesu|ts: We ldenued 63 proLelns, one of whlch was peroxlredoxln 2 (rx2), an anu-oxldauve enzyme. uslng lmmunocyLochemlsLry, anubodles agalnsL rx2 were found Lo blnd Lo Lhe cell surface of llve PuvLCs. lgC anubodles Lo rx2 were deLecLed ln 60 (18/30) of Lhe pauenLs wlLh ku, buL noL ln healLhy conLrols. lurLhermore, lgC anubodles Lo rx2 were deLecLed ln all LesLed ku pauenLs wlLh coronary arLery leslons. Sumulaung endoLhellal cells (LCs) wlLh anu-rx2 anubodles resulLed ln lncreased P2C2levels ln Lhe cell lysaLes. 1he anu-rx2 anubodles also lncreased varlous lnammaLory cyLoklne secreuons slgnlcanLly, ln parucular, lL-6 ln PuvLCs and C-CSl ln human coronary arLery LCs. ln addluon, anu-rx2 anubodles lnduced Lhe lncreased expresslon of adheslon molecules, such as L-selecun and lCAM-1, on LCs. LC LLlSA lndlcaLed LhaL rx2 proLelns were released from LCs sumulaLed by lnammaLory cyLoklnes. 8y Lhemselves, rx2 proLelns lnduced varlous lnammaLory cyLoklne secreuons, such as lL-6, lL-8, 1nl-o and CM-CSl, from LCs, and Lhe expresslon of adheslon molecules such as L-selecun and lCAM-1 on LCs. lnLeresungly, Lhese eecLs of rx2 proLelns were enhanced slgnlcanLly by Lhe appearance of anu-rx2 anubodles and were lnhlblLed slgnlcanLly by blocklng 1oll-llke recepLor 4 (1L84) slgnallng wlLh a 1L84-speclc lnhlblLory pepude. Cllnlcally, Lhe durauon of fever (>37.3C) ln ku pauenLs was slgnlcanLly longer ln Lhe anu-rx2-posluve group Lhan ln Lhe anu-rx2-negauve group. 1here was no slgnlcanL dlerence ln lnammaLory markers such as whlLe blood cell counLs and C-reacuve proLeln beLween boLh groups. Conc|us|on: lgC anubodles Lo rx2 are expecLed Lo be useful markers for ku. Lxpresslon of endoLhellal adheslon molecules and lnammaLory cyLoklne producuon are lnduced by Lhe blndlng of anu-rx2 anubodles Lo rx2 proLelns on LCs, and by Lhe acuvauon of 1L84 by exLracellular rx2 proLelns, whlch could resulL ln endoLhellal ln[ury. lurLhermore, anu-rx2 anubodles may cause endoLhellal ln[ury by lnhlblung Lhe anu-oxldauve acuvlLy of lnLracellular rx2 proLelns.D|sc|osures: k. karasawa, none.11:30 tu2646. Cost-Lecnveness Ana|ys|s of 1r|p|e 1herapy Versus Ltanercept |us Methotrexate |n Lar|y Aggress|ve kheumato|d Arthr|ns: Ana|ys|s 8ased on the 1LAk 1r|a|Pawre !alal, unlverslLy of MlnnesoLa, Mlnneapolls, Mn and ka|eb M|chaud, nauonal uaLa 8ank for 8heumauc ulseases & unlverslLy of nebraska Medlcal CenLer, Cmaha, nL8ackground]urpose: 1he long-Lerm cosL-eecuveness of Lrlple Lherapy (meLhoLrexaLe [M1x], sulfasalazlne [SSZ], hydroxychloroqulne [PCC]) dlsease modlfylng anu-rheumauc drugs (uMA8us) compared Lo a comblnauon of M1x and anu-1nl Lherapy ln pauenLs wlLh early rheumaLold arLhrlus (8A) ls unknown. ln Lhls sLudy, we used pauenL-level daLa from Lhe 1reaLmenL of Larly Aggresslve 8A (1LA8) Lrlal and Lhe nauonal uaLa 8ank for 8heumauc ulseases (nu8) Lo evaluaLe Lhe cosL-eecuveness of lmmedlaLe comblnauon Lherapy (wlLh blologlc or non-blologlc uMA8us) versus sLepplng up Lo comblnauon Lherapy aL 6 monLhs lf dlsease acuvlLy perslsLs desplLe M1x monoLherapy. 1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 109 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouooMethods: We developed a Markov slmulauon model Lo esumaLe quallLy-ad[usLed llfe years (CAL?s) and cosLs assoclaLed wlLh Lhe LreaLmenL sLraLegles examlned ln Lhe 1LA8 Lrlal.We evaluaLed four sLraLegles: lmmedlaLe Lrlple (l1), lmmedlaLe eLanercepL (lL), sLep-up Lrlple (S1), and sLep-up eLanercepL (SL).1he sLep-up sLraLegles lnvolved swlLchlng Lhose wlLh perslsLenL dlsease acuvlLy (uAS28 >= 3.2) from M1x monoLherapy Lo M1x plus elLher eLanercepL or Lrlple Lherapy aL 6 monLhs.1he slmulauon model exLends Lhe 2-year Lrlal Lo Lhe llfe-ume horlzon, uslng parameLers Laken from longlLudlnal nu8 daLa for Lherapy dlsconunuauon raLes, PAC Lransluons, and uAS28-PAC-CAL? mapplngs as well as Lhe publlshed llLeraLure for dlrecL and lndlrecL cosL esumaLes.Annual dlsconunuauon raLes of Lrlple Lherapy and eLanercepL from Lhe nu8 were esumaLed Lo be 22 and 10, respecuvely. 1hose who dlsconunued were assumed Lo conunue Lo recelve meLhoLrexaLe.Markov healLh sLaLes were dened by uAS28. uAS28 score Lransluons were obLalned dlrecLly from lndlvldual pauenLs ln Lhe Lrlal. ueaLh was modeled as an addluonal sLaLe wlLh background morLallLy esumaLed from Lhe 2007 uS Llfe 1ables. PAC scores were used as a secondary varlable Lo esumaLe CAL?s, 8A-speclc morLallLy, and dlrecL and lndlrecL cosLs (e.g., due Lo producuvlLy loss). We assumed a 3-monLh cycle lengLh, and dlscounLed boLh cosLs and eecuveness by 3 annually. kesu|ts: 1he eLanercepL sLraLegles (SL and lL) were more cosLly Lhan Lhe Lrlple sLraLegles (S1 and l1) malnly due Lo LreaLmenL cosLs [1able].1he llfeume beneLs from l1, S1 and SL were numerlcally slmllar (wlLhln 0.06 CAL?s).AlLhough lL was more eecuve Lhan l1, Lhe lncremenLal cosL-eecuveness rauo (lCL8) of lL relauve Lo l1 was $837,100/CAL?.1hese resulLs were robusL Lo parameLrlc sensluvlLy analyses. Conc|us|on: We used pauenL-level daLa from Lhe 1LA8 Lrlal, and Lhen pro[ecLed Lhelr llfeume cosLs and beneLs uslng Lhe nu8.1he beneLs from all sLraLegles were comparable, buL blologlcs sLraLegles were almosL Lwlce more expenslve Lhan Lrlple sLraLegles, produclng lCL8s greaLer Lhan whaL mosL healLhcare semngs nd accepLable. Cost-Effectiveness Analysis of TEAR StrategiesTreatment Strategies Cost ($)Effectiveness (QALY)Incremental Cost ($)*Incremental Effectiveness (QALY)*ICER ($/QALY)Immediate Triple (IT) 152,400 9.991Reference StrategyStep-up Triple (ST) 154,900 9.928 2500 -0.063Excluded (dominated by IT, more effective)Step-up Etanercept (SE)269,500 9.929 117,100 -0.062Excluded (dominated by IT, more effective)Immediate Etanercept (IE)338,100 10.213 185,700 0.222 837,100*Compared to ITD|sc|osures: n. Ia|a|, none, k. M|chaud, unlverslLy of nebraska Medlcal CenLer, 3, nauonal uaLa 8ank for 8heumauc ulseases, 3.11:43 tu2647. kecomb|nant Monoc|ona| Annbod|es Der|ved Irom S|ng|e CD19+ Synov|a| 8 Ce||s of kheumato|d Arthr|ns anents W|th 1ernary Lympho|d Structures D|sp|ay a Strong Immunoreacnv|ty 1owards C|tru|||nated n|stonesLllsa Corslero, Wllllam Parvey 8esearch lnsuLuLe, CMuL, London, unlLed klngdom8ackground]urpose: 8heumaLold arLhrlus (8A) ls characLerlsed by breach of self-Lolerance Lowards clLrulllnaLed proLelns. Around 40 of pauenLs dlsplay synovlal Leruary lymphold sLrucLures (1LS) wlLh funcuonal 8 cell folllcles supporung a germlnal-cenLre response and local auLoanubody producuon (1). Powever, Lhe naLure of Lhe maln (auLo)anugenlc reacuvlLy of synovlal 8 cells ls unknown. Pere we characLerlzed Lhe auLoreacuve 8 cell response of leslonal 8 cells lsolaLed from 1LS+ 8A synovlum. Methods: Slngle Cu19+ 8 cells were lACS sorLed from synovlal cell suspenslon of 4 1LS+ 8A pauenLs. 8nA was used Lo ampllfy lg vP and vL genes and C8 producLs were cloned and expressed as recomblnanL monoclonal anubodles dlsplaylng ldenucal speclclLy of Lhe orlglnal 8 cells (2). 8ecomblnanL anubodles were Lhen LesLed 1) Lo deLermlne Lhe frequency of polyreacuve clones and 2) Lo dene Lhelr lmmunoreacuvlLy Lowards nauve and clLrulllnaLed anugens uslng a synovlal anugen mlcroarray plauorm (3). kesu|ts: We obLalned 139 lndlvldual vP sequences of whlch 33 were lgM, 40 lgC, 27 lgA and 173 vL sequences and we generaLed a LoLal of 66 compleLe (P+L chalns) recomblnanL monoclonal anubodles. Analysls of Lhe vP gene somauc muLauon raLe showed evldence of anugen selecuon and lnLra-synovlal clonal dlverslcauon. no skewed dlsLrlbuuon of Lhe vP and vL gene usage was observed. Around 30 of synovlal monoclonal anubodles were reacuve Lowards clLrulllnaLed hlsLones ln Lhe anugen mlcroarray, ln parucular clLP2A and clLP28. 1hls reacuvlLy was conrmed by clLP2A and clLP28 LLlSA. Moreover, reacuvlLy Lowards Lhe clLrulllnaLed form of brlnogen was observed. Conc|us|on: Pere we provlded novel evldence LhaL hlghly muLaLed, locally dlerenuaLed 8 cells wlLhln 8A synovlal germlnal cenLre-llke sLrucLures dlsplay a sLrong lmmunoreacuve blas Lowards clLrulllnaLed hlsLones. 1hls suggesLs LhaL clLrulllnaLed hlsLones are Lhe maln anugens drlvlng ln slLu 8 cell acuvauon and dlerenuauon susLalnlng Lhe humoral auLolmmune response wlLhln Lhe 8A [olnLs. 8eferences:1. Pumby l, 8ombardlerl M, Manzo A, kelly S, 8lades MC, klrkham 8, Spencer !, lLzalls C. LcLoplc lymphold sLrucLures supporL ongolng producuon of class-swlLched auLoanubodles ln rheumaLold synovlum. LoS Med. 2009 !an 13,6(1):e1 2. Wardemann P, ?urasov S, Schaefer A, ?oung !W, Mere L, nussenzwelg MC. redomlnanL auLoanubody producuon by early human 8 cell precursors. Sclence. 2003 Sep 3,301(3638):1374-7 3. 8oblnson WP, ulCennaro C, Pueber W, Paab 88, kamachl M, uean L!, lournel S, long u, Cenovese MC, de vegvar PL, Skrlner k, Plrschberg uL, Morrls 8l, Muller S, rul[n C!, van venrool[ W!, Smolen !S, 8rown C, SLelnman L, uLz !. AuLoanugen mlcroarrays for muluplex characLerlzauon of auLoanubody responses. naL Med. 2002 Mar,8(3):293-301.D|sc|osures: L. Cors|ero, none.noou2648. Character|zanon of n|sndy|-tkNA Synthetase Spec|hc 1h Ce|| kesponse |n 8|ood and 8roncheoa|veo|ar Lavage (8AL) of Myos|ns anentsInka A|brecht, karollnska unlverslLy PosplLal, ueparLmenL of Medlclne, Solna, unlL of 8heumaLology, SLockholm, Sweden8ackground]urpose: ldlopaLhlc lnammaLory myopaLhy ls a rare chronlc lnammaLory dlsease LhaL ls assoclaLed wlLh Lhe presence of auLoanubodles polnung Lo a conLrlbuuon of adapuve lmmune responses Lo dlsease manlfesLauon. Cne of Lhe mosL frequenL myoslus-speclc auLoanubodles ls ralsed agalnsL hlsudyl-L8nA synLheLase (!o1). 1hls auLoanubody can be deLecLed ln 20 of myoslus pauenLs and ls assoclaLed 1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 110- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoowlLh lnLersuual lung dlsease (lLu). lLu may precede myoslus sympLoms lmpllcaung LhaL Lhe auLolmmune reacuon may sLarL ln Lhe lungs. 1he release of !o1 and fragmenLs Lhereof lnLo Lhe exLracellular mllleu ls belleved Lo Lrlgger boLh acuvauon of 1 cells by anugen-presenung cells and lnux of CC83 expresslng cells e.g. dendrluc cells and 1h1 lymphocyLes. So far, Lhere ls only llmlLed knowledge abouL !o1-reacuve 1 cells ln myoslus pauenLs. Methods: A candldaLe 1 cell eplLope was predlcLed from Lhe n-Lermlnal parL of Lhe !o-1 proLeln. ln order Lo ldenufy and characLerlze !o1 anugen-speclc 1h cells, we sumulaLed perlpheral blood (n=9) and 8AL cells (n=3) of myoslus pauenLs wlLh elLher recomblnanL !o1 proLeln or Lhe 13aa pepude coverlng Lhe predlcLed eplLope. SubsequenLly, Cu3+Cu4+1 cells were analyzed for up-regulauon of Cu40L by ow cyLomeLry aL day 3. ln addluon, 1 cells were examlned for eecLor funcuons by measurlng expresslon of lnLracellular cyLoklnes. llnally we compared Lhe phenoLype of 1 cells ln blood and 8AL (n=4) by sLalnlng for 1h1 assoclaLed chemoklne recepLors. kesu|ts: Sumulauon of cells from blood and 8AL wlLh !o1 proLeln caused a hlgh up-regulauon of Cu40L on Cu3+Cu4+ - cells. 1hus, !o1-speclc Cu4+1 cells can be deLecLed ln boLh blood and 8AL uld of myoslus pauenLs. upon acuvauon, !o1-speclc 1 cells malnly show 1h1 eecLor funcuons as evldenL by llng expresslon. Sumulauon of cells wlLh Lhe 13aa pepude correspondlng Lo our novel candldaLe 1 cell eplLope also resulLed ln a hlgh up-regulauon of Cu40L. Moreover, !o1-reacuve 1 cells are hlghly enrlched ln Lhe 8AL uld. 1hose anugen-speclc 1 cells have a hlghly pronounced 1h1 phenoLype as around 60 produce llng ln response Lo anugen sumulauon compared Lo only 10 llng responders ln Lhe correspondlng blood samples. lnLeresungly, 8AL 1 cells were all (100) posluve for CxC83 and CC83, Lwo chemoklne recepLors speclcally expressed on 1h1 cells. ln conLrasL, Cu4+- cells derlved from blood only showed 20 posluvlLy for CC83 and CxC83 expresslon, respecuvely. Conc|us|on: ln Lhls sLudy, we were able Lo demonsLraLe presence of !o1-reacuve Cu4+ 1 cells ln lnammaLory myopaLhles and Lhus provlde evldence LhaL Lhose 1 cells do reacL wlLh eplLopes on Lhls auLoanugen. !o1 reacuve Cu4+ 1 cells are also presenL ln Lhe lung and show here pronounced 1h1 eecLor funcuons. Moreover, we were able Lo ldenufy a novel 1 cell eplLope of Lhe hlsudyl-L8nA synLheLase. 1hls wlll open up new ways for sLudylng dlsease mechanlsms and mlghL provlde novel sLarung polnLs for Lherapeuuc lnLervenuon.D|sc|osures: I. A|brecht, none.12:13 ru2649. k|tux|mab for 1he 1reatment of IgG4-ke|ated D|sease: A rospecnve C||n|ca| 1r|a|Mollle CarruLhers, Massachuseus Ceneral PosplLal, 8osLon, MA and !ohn SLone, Massachuseus Ceneral PosplLal, Parvard Medlcal School, 8osLon, MA8ackground]urpose: lgC4-relaLed dlsease (lgC4-8u) ls a mulu-organ, bro-lnammaLory dlsorder. An open label plloL Lrlal of rlLuxlmab (81x) ln lgC4-8u conducLed aL LwocenLershas enrolled 29 of Lhe LargeLed 30 pauenLs.We reporL prellmlnary resulLs on28 pauenLsfollowed for a mlnlmum of one monLh. Methods: 1he Lrlal was approved by lnsuLuuonal revlew boards aL Lhe Massachuseus Ceneral PosplLal and Mayo Cllnlc. All pauenLs had hlsLopaLhologlcally-proven dlagnoses of lgC4-8u, lncludlngaL leasL Lwo ouL of Lhe Lhree ma[or feaLuresoymphoplasmacyuc lnlLraLe, sLorlform brosls, and obllLerauve phleblus Anu lmmunoperoxldase sLalnlng >10 lgC4+ plasma cells per Pl and a >40 lgC4/lgC rauo.All pauenLs had acuve dlsease, based on Lhe lgC4-8u 8esponder lndex (lgC4-8u 8l). auenLs were LreaLed wlLh 81x(1000 mg) umes Lwo doses (days 0 and 13) buL noL LreaLed wlLh malnLenance 81x. auenLs recelved meLhylprednlsolone 100 mg wlLh each 81x dose.1rlal vlslLs were performed aL 1, 3, 3, 6, 8, 10, and 12 monLhs aer Lhe rsL rlLuxlmab lnfuslon. 1he prlmary ouLcome was dened by Lhree measures: 1) dlsease response (decrease of responder lndex of >2 polnLs from basellne), 2) no dlsease ares before monLh 6, and, 3) no glucocorucolds beLween monLhs 2 and 6. CompleLe remlsslon was dened as an lgC4-8u 8l dlsease acuvlLy score of zero. kesu|ts: 1he organ sysLem lnvolvemenL among pauenLs ln Lhe Lrlal spanned Lhe full specLrum of lgC4-8u, lncludlng Lhe orblLs, sallvary glands, hypopharynx, lungs, lymph nodes, perlcardlum, pancreas, blllary Lree, reLroperlLoneum, kldney, prosLaLe, and oLhers. 1he mean lgC4-8u 8l aL basellne was 12.7 (range: 3 - 36).1he mean serum lgC4 concenLrauon was 334 mg/dL (normal < 121, range: 22 - 4780), buL 12 pauenLs (43) had normal values aL basellne.rednlsone was used concomlLanLly wlLh 81x aL basellne for remlsslon lnducuon ln only 2 of Lhe 28 pauenLs.1wenLy-slx of Lhe 28 pauenLs followed for aL leasL one monLh and 22 of 24 followed for Lhree monLhs achleved sLerold-free achleved dlsease responses (93 and 92 aL Lhese Lwo umepolnLs, respecuvely).Among Lhe 23 pauenLs compleung slx monLhs of follow-up Lo daLe, 20 (87) have achleved Lhe prlmary ouLcome. Cnly 2 of Lhe 28 pauenLs requlred an lncrease ln prednlsone dose aer MonLh 1. 1wo pauenLs were hosplLallzed durlng Lhe sLudy, one for Leglonnalre's dlsease (pre-basellne lnfecuon) and Lhe oLher for a cold aggluunln-medlaLed auLolmmune hemolyuc anemla.no serlous adverse evenLs relaLed Lo rlLuxlmab were reporLed. Conc|us|on: 8lLuxlmab has promlse as a safe, eecuve LreaLmenL for lgC4-8u.LxcellenL dlsease responses have been observed Lo daLe desplLe Lhe absence of concomlLanL glucocorucold use ln Lhls Lrlal.D|sc|osures: M. Carruthers, none, I. Stone, none.ACk MLL1 1nL kCILSSCk SLSSICNS 12:4S - 2:1S rmAJmlssloo to Meet tbe ltofessot sessloos tepoltes o sepotote teqlsttouoo ooJ ucket. 1o vetlfy wblcb sessloo yoo teqlsteteJ fot, tbe teqlsttouoo coJe oo yoot ucket oeeJs to motcb tbe J-Jlqlt coJe lo poteotbeses below. lf yoo ote lotetesteJ lo potuclpouoq lo ooe of tbese sessloos ot excbooqloq yoot ucket, vlslt tbe Ack teqlsttouoo Jesk to cbeck spoce ovolloblllty. vlew tbe sessloo ovetvlew oolloe lo My 4nnuo/ Meennq ot www.Ackooooolmeeuoq.otq. * 5essloos JeooteJ wltb oo ostetlsk wete solJ oot os of Aoqost J0.12Adu|t Inammatory Myopathy (071)Speaker: 8oberL L. WorLmann, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - revlew Lhe cllnlcal manlfesLauons of lnammaLory myopaLhles lncludlng lmporLanL exLra-muscle manlfesLauons- dlscuss dlagnosuc pearls for Lhe evaluauon of someone suspecLed of havlng an lnammaLory myopaLhy- dlscuss Lhe LreaLmenL paradlgm for lnammaLory myopaLhlesCAnCLLLLu1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 111 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo138as|c Immuno|ogy for C||n|ca| kheumato|og|sts (072)Speaker: AnLony 8osen, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe how Lhe lmmune sysLem funcuons ln normal lndlvlduals- ldenufy abnormallues of lmmune regulauon LhaL lead Lo auLolmmunlLy14 A*8ehet's D|sease (073)Speaker: ?usuf ?azlcl, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - dlscuss Lhe epldemlology, dlsease mechanlsms and Lhe dlerenual dlagnosls of 8eheL's syndrome- descrlbe currenL approaches Lo Lhe managemenL of pauenLs wlLh 8eheL's syndrome14 8*Infecnons W|th 8|o|og|cs (074)Speaker: kaLhryn P. uao, Muupoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - dlscuss Lhe rlsk of lnfecuon relaLed Lo lnammauon and dlsease- dlscuss Lhe rlsk facLors for lnfecuon- recognlze Lhe magnlLude of rlsk lmposed by sLerolds and blologlcs- deLermlne Lhe approach Lo rlsk reducuon (18 and SlL)1S Aed|atr|cs: D|mcu|t to 1reat Iuven||e Id|opath|c Arthr|ns (07S)Speaker: 1homas !. A. Lehman, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - dlscuss Lhe dlerences ln Lhe LreaLmenL of Lhe dlmculL slLuauons for Lhe dlerenL subLypes of [uvenlle ldlopaLhlc arLhrlus- recognlze some of Lhe compllcauons of Lhe dlsease and approprlaLe managemenL- explaln Lhe dlmculues posed by non-adherence and lnadequaLe declslon maklng1S 8*sor|anc Arthr|ns (076)Speaker: M. Llalne Pusnl, Mu, MP upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - dlscuss advances ln dlagnosls and classlcauon of psorlauc arLhrlus- deLermlne lf pauenLs wlLh psorlauc arLhrlus should be LreaLed aggresslvely- deLermlne LreaLmenL opuons for pauenLs wlLh psorlauc arLhrlus16 A*kheumato|d Arthr|ns: 8|o|og|ca| Agents (077)Speaker: Ldward keysLone, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe Lhe newer Lrends ln Lhe use of blologlcs- dlscuss Lhe emerglng blologlcs, lncludlng bloslmllars, and Lhelr advanLages for Lhe Lherapeuuc algorlLhm- descrlbe Lhe rlsk/beneL proles of blologlc agenLs16 8*kheumato|d Arthr|ns: Cha||eng|ng Cases (078)Speaker: !onaLhan kay, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - dlscuss Lhe managemenL of pauenLs wlLh refracLory rheumaLold arLhrlus- ldenufy novel LreaLmenL opuons for Lhose falllng convenuonal Lheraples- creaLe eecuve managemenL plans for compllcaLed rheumaLold arLhrlus pauenLs17 A*System|c Lupus Lrythematosus: Lupus Nephr|ns (079)Speaker: 8rad P. 8ovln, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - revlew lmmunosuppresslve Lherapy of lupus nephrlus Classes ll-v, lncludlng novel blologlcs- dlscuss Lhe use of renoproLecuve and anu-proLelnurla Lheraples ln lupus nephrlus- dlscuss dlagnosls and LreaLmenL of renal Lhrombouc mlcroanglopaLhy and podocyLopaLhles- ouLllne Lhe fuLure research agenda for cllnlcal Lrlals ln lupus nephrlus17 8Vascu||ns: Update (080)Speaker: 8aashld A. Luqmanl, uM upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe Lhe currenL denluons of vascullus accordlng Lo aecLed vessel slze- dlscuss Lhe role of slmple cllnlcal evaluauon alongslde Lhe varlous avallable laboraLory and lmaglng LesLs, lncludlng anu-neuLrophll cyLoplasm anubodles- ldenufy currenL and novel Lherapeuuc modalluesACk SLSSICNS 1:00 - 2:00 rm6 CAn|ma| Mode|s |n kheumanc D|seasenow Usefu| Are 1hey? PM PS

ModeraLor: uana . Ascherman, Mu Speaker: Wllllam 8ldgway, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - conrm anlmal models as Lools Lo sLudy mechanlsms lnvolved ln organ-based as well as sysLemlc auLolmmune dlsease- llsL Lhe poLenual uullLy of anlmal models ln Lhe developmenL of novel Lherapeuuc sLraLegles- ldenufy Lhe llmlLauons of anlmal models as repllcaLes of human dlsease1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 112- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo8a||room 20 Anench Lecture: Lvo|unonary Med|c|ne and Chron|c Inammatory State - known and New Concepts |n athophys|o|ogy PM PS

ModeraLor: Lrlc L. Maueson, Mu, MP Speaker: 8alner P. SLraub, Muupoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - recall sysLemlc neuroendocrlne responses ln chronlc lnammaLory dlseases are ughLly regulaLed along Lhe clrcadlan rhyLhm Lo allocaLe energy-rlch fuels from sLores Lo an acuvaLed lmmune sysLem-descrlbe how Lhe neuroendocrlne lmmune neLwork has been evoluuonarlly posluvely selecLed Lo serve shorL-llved lnammauon buL noL long-sLandlng lnammaLory dlseases - role of anLagonlsuc pleloLropy- classlfy lmporLanL sysLemlc dlsease sequelae of chronlc lnammaLory dlseases (meLabollc syndrome, anemla, depresslon/faugue eLc) as consequence of long-sLandlng mlsgulded energy regulauon- explaln how sysLemlc neuroendocrlne responses ln chronlc lnammaLory dlseases are parL of euology and dlsease-aggravaung per sena|| 81Inammatory Lye D|sease: An Update for kheumato|og|sts PM PS

ModeraLors: Shelly . kaa, Mu and MargareL 8. Wllkes, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe Lhe baslc anaLomlcal sLrucLures of Lhe eye- dlscuss Lhe paLhogenesls and dlerenual dlagnosls of lnammaLory ophLhalmlc dlseases- revlew poLenual LreaLmenL sLraLegles for Lhe pauenL wlLh lnammaLory eye dlsease1:00 ruInammatory Lye D|sease: A Comprehens|ve kev|ew for kheumato|og|stsCeorge apallodls, Mu 1:30 ru1reatment of Inammatory Lye D|sease by the kheumato|og|stSerglo SchwarLzman, Mu ACk S1UD GkCUS 1:00 - 2:00 rm31 CA Mu|n-D|sc|p||nary Approach to ost Iracture Management Study Group 1:00 ruA Mu|n-D|sc|p||nary Approach to Secondary Iracture revennon: ark N|co||et Method|st nosp|ta|!ohn 1. Schousboe, Mu, hu 1:13 ruA kheumato|og|c rotoco| for Csteoporonc Iracture ManagementColleen WaLklns, Mu 1:30 ruA Iracture L|a|son Serv|ce |n a Mu|n-Spec|a|ty racnce: kheumato|ogy and Crthoped|csLlnda k. Myers, Mu 1:43 ruCost Lecnveness of Iracture L|a|son Serv|cesuanlel P. Solomon, Mu, MP 32 AAnnphospho||p|d (AS) Study Group 1:00 ruMechan|sms of Adverse regnancy Cutcomes |n Women W|th Annphospho||p|d Annbod|esvlkke Abrahams, hu 1:13 ruUpdate on D|agnos|s and Management of Cbstetr|c ASWare 8ranch, Mu 1:30 ru1he ko|e of 1|ssue Iactor |n ASnlgel Mackman, hu 1:43 ruUpdate on Standard|zanon of Annphospho||p|d AnnbodySllvla S. lerangell, hu 306 ALxpert Iourna| C|ub Study Group 1:00 ruSe|f-cr|nc|sm |n Manuscr|pt reparanon1heodore lncus, Mu1:23 ruSe|ecnon 8|asSamy Sulssa, hu1:40 ruMeasur|ng Lecnveness1heodore lncus, Mu32 8Gout C|ass|hcanon Cr|ter|a Study Group 1:00 ruSystemanc L|terature kev|ew of Imag|ng |n Goutnlcola ualbeLh, M8Ch8, Mu 1:23 rukheumato|og|sts' Competency |n Crysta| D|agnos|s1lm L. !ansen, Mu, hu 1:30 ru8a|anc|ng Sens|nv|ty and Spec|hc|ty |n Gout C|ass|hcanon1uhlna neogl, Mu, hu 1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 113 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo Sapph|re Anypermob|||ty Study Group 1:00 ruA kheumato|og|st's u|ck Gu|de to Genenc 1esnng |n nypermob|||ty-ke|ated D|sorderslranslska MalfalL, Mu, hu 1:13 ruro|apse, Sexua| rob|ems and Inconnnence |n Iema| anents W|th 8en|gn Io|nt nypermob|||ty SyndromePelenl MasLoroudes, M88S 1:30 runypermob|||ty and the Comp|ex keg|ona| a|n Syndrome]I|bromya|g|a Syndrome]Chron|c Iangue SyndromeCver|apPelen Cohen, Mu, hu 1:43 rusycho|og|ca| Aspects of the nypermob|||ty SyndromeCarollna 8aeza-velasco, hu 28 DIntersnna| Lung D|seases (ILD) |n Connecnve 1|ssue D|sease Study Group 1:00 ru1reatment of u|monary nypertens|on |n anents W|th ILDAryeh llscher, Mu1:23 ru1he ko|e of keux and Asp|ranon |n ILDaul l. uellarlpa, Mu 1:30 ruC||n|ca| Use of Auto Annbod|es |n Myos|nsMasaLaka kuwana, Mu, hu Ind|go CMacrophage Acnvanon Syndrome (MAS) Study Group 1:00 ruDeve|opment and Va||danon of C||n|ca| D|agnosnc Cr|ter|a for MASAngelo 8avelll, Mu 1:13 ruerfor|n Mutanons and o|ymorph|sms |n System|c Iuven||e Id|opath|c Arthr|ns and MASnlco M. WulraaL, Mu, hu 1:30 ruIL-6 |n the Deve|opment of MASlabrlzlo ue 8enedem, Mu, hu 1:43 ruNove| Degranu|anon Assays for the D|agnos|s of MAS?enan 8ryceson, hu Ind|go DMyos|ns Study Group 1:00 ru1he n|story and Current Status of C|ass|hcanon Cr|ter|a for Adu|t and Iuven||e Dermatomyos|ns and o|ymyos|nslngrld L. Lundberg, Mu, hu 1:23 ru1he n|story and Current Status of C|ass|hcanon Cr|ter|a for Inc|us|on 8ody Myos|nsAnLhony A. AmaLo, Mu 1:30 ruCpen D|scuss|on of Myos|ns C|ass|hcanon Cr|ter|alrederlck W. Mlller, Mu, hu Sapph|re INon-Vascu||nc Vascu|opathy Study Group 1:00 ruCrgan-Spec|hc atho|ogy |n Degos D|sease and S|m||ar|ty to Non-Vascu||nc kheumanc Vacu|opath|esCynLhla Magro, Mu 1:20 ru1he Genencs of Vascu|ar kemode||ngManfred 8oehm, Mu 1:40 ruL|nkage Ana|ys|s |n kare Vascu|opath|esMarc Lewls, hu 29DCsteoarthr|ns Study Group 202 ASpondy|oarthr|ns Study Group 1:00 ruChron|c Low 8ack a|n |n the U.S.: Lconom|c and C||n|ca| ImpactMlchael P. Welsman, Mu 1:23 ruInammatory 8ack a|n |n the U.S.!ohn u. 8evellle, Mu 1:30 ruSpondy|arthr|ns Marun 8udwalelL, Mu 28 81akayasu's Arter|ns Study Group 1:00 ruCore D|sease Doma|ns to be Measured |n 1akayasu's Arter|nsSlbel Z. Aydln, Mu 1:13 ruUn||ty of Current Compos|te Measures for 1akayasu's Arter|nsPaner ulreskenell, Mu 1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 114- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo1:30 ruUn||ty of Magnenc kesonance Imag|ng and os|tron Lm|ss|on 1omography as Cutcome Measure |n 1akayasu's Arter|nsuanlel 8lockmans, Mu, hu 1:43 ruC||n|ca| 1r|a| Des|gn Cpnons |n 1akayasu's Arter|nseLer A. Merkel, Mu, MP ACk WCkkSnCS 1:1S - 3:1S rmAJmlssloo to wotksbops tepoltes o sepotote teqlsttouoo ooJ ucket. 1o vetlfy wblcb sessloo yoo teqlsteteJ fot, tbe teqlsttouoo coJe oo yoot ucket oeeJs to motcb tbe J-Jlqlt coJe lo poteotbeses below. lf yoo ote lotetesteJ lo potuclpouoq lo ooe of tbese sessloos ot excbooqloq yoot ucket, vlslt tbe Ack teqlsttouoo Jesk to cbeck spoce ovolloblllty. vlew tbe sessloo ovetvlew oolloe lo My 4nnuo/ Meennq ot www.Ackooooolmeeuoq.otq. * 5essloos JeooteJ wltb oo ostetlsk wete solJ oot os of Aoqost J0.2Io|nt In[ecnon 1echn|ques (237)Speakers: ALul A. ueodhar, Mu and kenneLh S. C'8ourke, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - dlscuss lndlcauons and conLralndlcauons for [olnL asplrauons and ln[ecuons- ldenufy and avold common mlsLakes ln [olnL ln[ecuon procedures- perform common [olnL and so ussue ln[ecuons on upper and lower exLremlues1 ACsteoporos|s: Interprenng Dua| Lnergy k-ray Absorpnometry and C||n|ca| k|sk Iactors: 1he New Iracture k|sk Assessment A|gor|thm (238)Speaker: SLuarL L. Sllverman, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - use bone mlneral denslLy and cllnlcal rlsk facLors ln deLermlnauon of absoluLe rlsk of fracLure- dlscuss Lhe concepL of lnLervenuon Lhreshold- address llmlLauons of l8Ax ln cllnlcal pracuce1 8kena| n|stopatho|ogy |n System|c Lupus Lrythematosus and Vascu||ns (239)Speaker: AnLhony Chang, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - ldenufy Lhe paLhologlc changes LhaL occur ln lupus nephrlus- dlscuss Lhe paLhologlc basls for Lhe classlcauon of lupus nephrlus and how lL relaLes Lo cllnlcal managemenL- descrlbe Lhe hlsLologlcal changes ln Lhe kldneys of pauenLs wlLh vascullusACk SLSSICN 1:30 - 2:00 rm6 AACk 8us|ness Meenng PM PS 1bls sessloo ls oot ellqlble fot cM cteJlt.ModeraLor: Audrey 8. uknls, Mu ACk, Ioundanon and Akn UpdatesL|ecnon of ACk 1reasurerL|ecnon of ACk 8oard of D|rector MembersInsta||anon of 77th ACk res|dentACk SLSSICNS 2:30 - 4:00 rm6 DAd|pose 1|ssue and Inammanon PM PS

ModeraLor: !ohn varga, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe Lhe blologlc mechanlsms llnklng adlpose ussue and lnammauon- dene Lhe mechanlsms for adlpose ussue modulauon of lnammaLory cell acuvlLy- dlsungulsh Lhe feaLures of meLabollc regulauon of macrophage funcuon2:30 ruInammanon, Metabo||c Syndrome and Cbes|ty!errold M. M. Clefsky, Mu 3:00 ruCbes|ty and Metabo||c kegu|anon of MacrophagesAnLhony W. lerranLe, !r., Mu, hu 3:30 ruMetabo||c kegu|anon of Innate Immun|tyA[ay Chawla, Mu, hu Ind|go LNove| Ins|ght |nto the athogenes|s of System|c Vascu||ns PM PS

ModeraLor: 8ula Pa[[-All, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - examlne recenL advances ln Lhe paLhogenesls of small and large vessel vascullus- descrlbe Lhe role of Lhe adapuve and lnnaLe lmmune sysLem ln Lhe paLhogenesls of small and large vessel vascullus- dene Lhe role of geneuc, eplgeneuc and envlronmenLal facLors ln Lhe paLhogenesls of small and large vessel vascullus2:30 ruathogenes|s of Sma|| Vesse| Vascu||ns8onald lalk, Mu 3:13 ruathogenes|s of Large Vesse| Vascu||nsCornella M. Weyand, Mu, hu 1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 115 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoona|| 81Csteoporos|s 1reatment Strateg|es for 1oday and 1omorrow PM PS ModeraLor: MargareL 8. Wllkes, Mu upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe currenL daLa regardlng blsphosphonaLe Lherapy and calclum supplemenLauon and adverse evenLs- evaluaLe Lhe evldence and besL daLa supporung durauon of blsphosphonaLe Lherapy for LreaLmenL osLeoporosls- revlew medlcauons assoclaLed wlLh drug lnduced bone loss and developLreaLmenL sLraLegles for managlng osLeoporosls ln pauenLs on Lhese agenLs- ldenufy poLenual new Lheraples for LreaLmenL of osLeoporosls2:30 ruCa|c|um, V|tam|n D & 8|sphosphonates - 8enehts, k|sks and Drug no||daysMlchael McClung, Mu 3:00 ruMed|canon Induced Csteoporos|s: C||n|ca| Imp||canons for the kheumato|og|stMary 8eLh Pumphrey, Mu, hu 3:30 ruCsteoporos|s 1reatments on the nor|zonMlchael !. Marlclc, Mu 8a||room 20 AVacc|no|ogy and DMAkD Use |n Immunocomprom|sed and n|gh-k|sk opu|anons PM PS

ModeraLors: Leonard P. Calabrese, uC and !asvlnder A. Slngh, Mu, MP upoo compleuoo of tbls sessloo, potuclpoots sboolJ be oble to. - descrlbe Lhe daLa supporung relaLed Lo vacclnauon ln rheumaLold arLhrlus pauenLs- explaln Lhe lmpacL of blologlc and synLheuc uMA8us on vacclne response ln pauenLs wlLh rheumauc dlseases decreases Lhe rlsk of cardlac dlsease ln rheumaLold arLhrlus- assess Lhe safeLy and rlsks of use of blologlc uMA8us ln reproducuve lssues and durlng pregnancy and lacLauon2:30 ru8|o|og|cs Dur|ng re-concepnon, regnancy and LactanonLllza l. ChakarvarLy, Mu 3:00 ru1he Impact of DMAkD (b|o|og|c and non-b|o|og|c) 1herapy on Vacc|ne kesponses |n kheumanc D|sease: Imp||canons for racnce!erey 8. Curus, Mu, MP, MS 3:30 ruVacc|nanon |n Immunocomprom|sed anents |n 2013: What Does the Lv|dence 1e|| Us?kevln L. WlnLhrop, Mu, MP ACk CCNCUkkLN1 A8S1kAC1 SLSSICNS 2:30 - 4:00 rm6 ALate-break|ng Abstracts Sess|onModeraLor: ChesLer v. Cddls, Mu Ind|go DAnnphospho||p|d SyndromeModeraLors: ler Lulgl Meronl, Mu and !oyce 8auch, hu 2:30 ru26S0. S||ent Ischem|c neart D|sease |n anents W|th r|mary Annphospho||p|d SyndromeAnLonlo 8. Cabral1, Cregorla Cmez-Pernndez2, MarLha Morelos-Cuzmn3, 1auana 8odrlguez-8eyna4, Carlos AlberLo nunez-Alvarez3 and !orge vazquez-Lamadrld3, 1lnsuLuLo naclonal de Clenclas Medlcas y nuLrlclon Salvador Zublrn, Mexlco, Mexlco, 2lnsuLuLo naclonal ue Clenclas Medlcas y nuLrlcln Salvador Zublrn, Mexlco, Mexlco, 3lnsuLuLo naclonal de Clenclas Medlcas y nuLrlclon Salvador Zublran, Mexlco ClLy, Mexlco, 4nauonal lnsuLuLe of Medlcal Sclences and nuLrluon, Mexlco ClLy, Mexlco, 3lnsuLuLo naclonal de Clenclas Medlcas y nuLrlcln Salvador Zublrn, Mexlco ClLy, Mexlco2:43 ru26S1. 1he Assoc|anon 8etween Annphospo||p|d Annbod|es and ke|ated C||n|ca| Cutcomes: A Cr|nca| kev|ew of 1he L|teratureCecllla 8. Chlghlzola1, Laura Andreoll2, Alessandra 8anzaLo3, Cullherme 8amlres de !esus4, Culllermo !. ons-LsLel3, uoruk Lrkan6 and Cn 8ehalf of AS Acuon7, 1lsuLuLo Auxologlco lLallano, unlverslLy of Mllan, Cusano Mllanlno, lLaly, 28heumaLology unlL, unlverslLy of 8rescla, 8rescla, lLaly, 3ueparLmenL of Cardlac 1horaclc and vascular Sclences, unlverslLy of adua, adua, lLaly, 4ueparLmenL of CbsLeLrlcs, unlversldade do LsLado do 8lo de !anelro, 8lo de !anelro, 8razll, 3ueparLmenL of AuLolmmune ulseases, lnsuLuL Cllnlc de Medlclna l uermaLologla, PosplLal Cllnlc, 8arcelona, Spaln, 6PosplLal for Speclal Surgery, new ?ork, n?, 7AS AC1lCn, new ?ork, n?3:00 ru26S2. Cvar|an keserve |n Women W|th r|mary Annphospho||p|d SyndromeLucas ?amakaml1, aulo Seranl2, uanlel 8. Arau[o3, Llolsa 8onf4, Llalne . Leon4, Ldmund C. 8aracaL4 and Clovls A. Sllva3, 1laculdade de Medlclna da unlversldade de So aulo, Sao aulo, 8razll, 2Mu, hu, Sao aulo, 8razll, 3laculdade de Medlclna da unlversldade de So aulo (lMuS), So aulo, 8razll, 4laculdade de Medlclna da unlversldade de So aulo, So aulo, 8razll, 3unlverslLy of So aulo, So aulo, 8razll3:13 ru26S3. Low V|tam|n D Is Assoc|ated W|th Increased k|sk of Venous 1hrombos|s |n System|c Lupus Lrythematosus, kegard|ess of Lupus Anncoagu|ant StatusMlchelle eLrl and Pong lang, !ohns Popklns unlverslLy School of Medlclne, 8alumore, Mu1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 116- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo3:30 ru26S4. IgG Annbod|es D|rected Aga|nst Doma|n I of 2-G|ycoprote|n I Are S|gn|hcant red|ctors of 1hromboembo||c Lvents In anents W|th Annphospho||p|d Annbod|es. A rospecnve Cohort StudySLephane Zully1, 8as de LaaL2, lrancls Culllemln3, lerre kamlnsky4, Pllde kelchLermans3, 8oger Albesa6, Cary L. norman6, Anne-Chrlsune 8aL7, hlllp de CrooL8, 1homas LecompLe9, veronlque 8egnaulL10 and uenls Wahl1, 1CPu de nancy, vascular Medlclne ulvlslon and 8eglonal CompeLence CenLer lor 8are vascular And SysLemlc AuLolmmune ulseases, nancy, l-34000, lrance, lnserm, uM8_S 1116, nancy, l-34000, lrance, unlverslLe de Lorralne, nancy, l-34000, lrance, nancy, lrance, 28lochemlsLry, CA8lM, MaasLrlchL unlverslLy, 1he neLherlands, Cllnlcal ChemlsLry and PemaLology, uMC uLrechL, 1he neLherlands, Synapse 8v, MaasLrlchL, 1he neLherlands, Sanquln 8esearch, AmsLerdam, 1he neLherlands, MaasLrlchL, neLherlands, 3CPu nancy, Cllnlcal Lpldemlology and Lvaluauon, unlverslLe de Lorralne, arls uescarLes unlverslLy, ALMAC, LA 4360, nancy, lrance, 4unlverslLe de Lorralne, nancy, l-34000, lrance, CPu de nancy, Crphan dlsease unlL, nancy, l-34000, lrance,, nancy, lrance, 38lochemlsLry, CA8lM, MaasLrlchL unlverslLy, 1he neLherlands, Synapse 8v, MaasLrlchL, 1he neLherlands, MaasLrlchL, neLherlands, 6lnCvA ulagnosucs, San ulego, CA, 7unlverslLe de Lorralne, nancy, l-34000, lrance, lnserm, ClC-LC ClL6, nancy, l-34000, lrance, CPu de nancy, Cllnlcal Lpldemlology and Lvaluauon ueparLmenL, nancy, l-34000, lrance, CPu de nancy, 8heumaLology deparLmenL, nancy, lrance, 8Cllnlcal ChemlsLry and PemaLology, uMC uLrechL, 1he neLherlands, uLrechL, neLherlands, 9lnserm, uM8_S 1116, nancy, l-34000, lrance, unlverslLe de Lorralne, nancy, l-34000, lrance, CPu de nancy, PaemaLology LaboraLory, nancy, l-34000, lrance, ulvlslon of PaemaLology, PuC, Ceneva, SwlLzerland (currenL address), Ceneva, SwlLzerland, 10lnserm, uM8_S 1116, nancy, l-34000, lrance, unlverslLe de Lorralne, nancy, l-34000, lrance, CPu de nancy, ConLraL d'lnLerface, nancy, l-34000, lrance, nancy, lrance3:43 ru26SS. 1herapeunc Lect of 2GI and Its Synthenc der|vanveLoaded 1o|erogen|c Dendr|nc Ce||s |n Lxper|menta| Annphospho||p|d Syndrome, |s Assoc|ated W|th m|kNA 23b, 142-3p and 221 Lxpress|on and 1regs Upregu|anonMlrl 8lank1, Sllvla S. lerangell2, Ponorlo 1orres-Agullar3 and ?ehuda Shoenfeld4, 1Zabludowlcz CenLer for AuLolmmune ulseases, Sheba Medlcal CenLer, 1el-Pashomer, amllaLed Lo Sackler Medlcal School, 1el Avlv unlverslLy, 8amaL Can, lsrael, 2unlverslLy of 1exas Medlcal 8ranch, CalvesLon, 1x, 3nauonal CenLer for 8lood 1ransfuslon, Mexlco ClLy, Mexlco, 4Zabludowlcz CenLer for AuLolmmune ulseases, Sheba Medlcal CenLer, AmllaLed Lo Sackler laculLy of Medlclne, 1el-Avlv unlverslLy,1el-Avlv, 1el-Avlv, lsrael28 8Lp|dem|o|ogy and nea|th Serv|ces kesearch VI: k|sk Iactors |n kheumanc D|sease Suscepnb|||tyModeraLors: ulane v. LaCallle, Mu and Laura L. 1arLer, Mu 2:30 ru26S6. erformance of red|cnon Mode|s for kheumato|d Arthr|ns Sero|og|c henotypes Among Women Us|ng Iam||y n|story, Genencs and Lnv|ronmenta| Iactors!erey A. Sparks1, Chla-?en Chen2, xla !lang3, Llnda 1. Plrakl4, Lars klareskog3, Lars Alfredsson3, karen P. CosLenbader1 and LllzabeLh W. karlson1, 18rlgham and Women's PosplLal, Parvard Medlcal School, 8osLon, MA, 2Parvard School of ubllc PealLh, 8osLon, MA, 3karollnska lnsuLuLeL, SLockholm, Sweden, 48rlgham and Women's PosplLal, Parvard School of ubllc PealLh, 8osLon, MA, 3karollnska unlverslLy PosplLal, karollnska lnsuLuLeL, SLockholm, Sweden2:43 ru26S7. Interacnons 8etween C|gareue Smok|ng, 8ody Mass Index and Inammatory Cytok|ne Leve|s |n Determ|n|ng the k|sk of Deve|op|ng kheumato|d Arthr|nsLllzabeLh v. Arkema1, Susan Malspels2, 8lng Lu2, Llnda 1. Plrakl3, LllzabeLh W. karlson4 and karen P. CosLenbader3, 1Parvard School of ubllc PealLh, 8osLon, MA, 28rlgham and Women's PosplLal, 8osLon, MA, 38rlgham and Women's PosplLal, Parvard School of ubllc PealLh, 8osLon, MA, 48rlgham and Women's PosplLal, Parvard Medlcal School, 8osLon, MA, 3ulvlslon of 8heumaLology, lmmunology and Allergy, 8rlgham and Women's PosplLal, Parvard Medlcal School, 8osLon, MA3:00 ru26S8. D|pepndy| epndase-4 Inh|b|tors |n 1ype 2 D|abetes May keduce 1he k|sk of Auto|mmune D|seasesSeoyoung C. klm1, Sebasuan Schneewelss1, 8oberL !. Clynn1, Mlchael uoherLy1, Alllson Coldne2 and uanlel P. Solomon3, 18rlgham and Women's PosplLal, 8osLon, MA, 2!oslln ulabeLes CenLer, 8osLon, MA, 3Parvard Medlcal School, 8rlgham and Women's PosplLal, ulvlslon of 8heumaLology, ulvlslon of harmacoepldemlology, 8osLon, MA3:13 ru26S9. Annbod|es to C|tru|||nated Lno|ase, I|br|nogen, and V|mennn Are Assoc|ated W|th Markerso Lndothe||a| Dysfuncnon |n I|rst-Degree ke|anves of anents W|th kheumato|d Arthr|ns: 1he Stud|es of the Lno|ogy Cf kheumato|d Arthr|ns!an M. Pughes-Ausun1, kendra A. ?oung2, kevln u. ueane3, Mlchael P. Welsman4, !ane P. 8uckner3, 1ed 8. Mlkuls6, !ames 8. C'uell7, 8lchard M. keaung8, eLer k. Cregersen9, !eremy Sokolove10, Wllllam P. 8oblnson11, v. Mlchael Polers3 and !lll M. norrls2, 1unlverslLy of Callfornla, San ulego, La !olla, CA, 2Colorado School of ubllc PealLh, Aurora, CC, 3unlverslLy of Colorado School of Medlclne, Aurora, CC, 4Cedars-Slnal Med CLr, Los Angeles, CA, 38enaroya 8esearch lnsuLuLe, Seaule, WA, 6Cmaha vA and unlverslLy of nebraska Medlcal CenLer, Cmaha, nL, 7unlverslLy of nebraska Medlcal CenLer, Cmaha, nL, 8-,* unlverslLy of Chlcago, Chlcago, lL, 9lelnsLeln lnsuLuLe for Medlcal 8esearch, ManhasseL, n?, 10vA alo AlLo PealLh Care SysLem and SLanford unlverslLy, alo AlLo, CA, 11SLanford unlverslLy School of Medlclne, SLanford, CA1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 117 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo3:30 ru2660. Cmega-3 Supp|ement Use Is Assoc|ated W|th a keduced k|sk of Ann-Cyc||c C|tru|||nated rote|n os|nv|ty |n a opu|anon W|thout kheumato|d Arthr|ns, 8ut At k|sk for Iuture D|sease8yan W. Can1, kendra A. ?oung1, Cary C. Zerbe2, M. krlsLen uemoruelle3, Mlchael P. Welsman4, !ane P. 8uckner3, eLer k. Cregersen6, 1ed 8. Mlkuls7, !ames 8. C'uell8, 8lchard M. keaung9, Mlchael !. Clare-Salzler10, kevln u. ueane3, v. Mlchael Polers3 and !lll M. norrls1, 1Colorado School of ubllc PealLh, Aurora, CC, 2Colorado School of ubllc PealLh / unlverslLy of Colorado AnschuLz Medlcal Campus, Aurora, CC, 3unlverslLy of Colorado School of Medlclne, Aurora, CC, 4Cedars-Slnal Medlcal CenLer, Los Angeles, CA, 38enaroya 8esearch lnsuLuLe, Seaule, WA, 6lelnsLeln lnsuLuLe for Medlcal 8esearch, ManhasseL, n?, 7Cmaha vA and unlverslLy of nebraska Medlcal CenLer, Cmaha, nL, 8unlverslLy of nebraska Medlcal CenLer, Cmaha, nL, 9-,* unlverslLy of Chlcago, Chlcago, lL, 10unlverslLy of llorlda, College of Medlclne, Calnesvllle, lL3:43 ru2661. hys|ca| Acnv|ty, Ad|pos|ty, and the k|sk of Gout |n Women: 1he Nurses nea|th StudyPyon k. Chol1, Llndsay C 8urns2, ?uqlng Zhang3, Sharan 8al1 and Cary Curhan4, 1ArLhrlus 8esearch CenLre of Canada, 8lchmond, 8C, 2unlverslLy of 8rlush Columbla, vancouver, 8C, 38osLon unlverslLy School of Medlclne, 8osLon, MA, 4Parvard Medlcal School, 8osLon, MA28 Dnea|th Serv|ces kesearch, ua||ty Measures and ua||ty of Care - Innovanons |n nea|th Care De||veryModeraLors: Salahuddln kazl, Mu and !lnoos ?azdany, Mu, MP 2:30 ru2662. ua||ty of Care red|cts D|sease Cutcomes Among anents W|th System|c Lupus Lrythematosus!lnoos ?azdany1, Laura 1rupln1, aLrlcla . kaLz1, Cabrlela Schma[uk1 and Ldward P. ?elln2, 1unlverslLy of Callfornla, San lranclsco, San lranclsco, CA, 2uC San lranclsco, San lranclsco, CA2:43 ru2663. Mov|ng 1owards ersona||zed nea|thcare: A anent keported Cutcome 8ased A|gor|thm Can A|d kheumato|og|sts and anents |n Mon|tor|ng kheumato|d Arthr|ns |n Da||y C||n|ca| racnce!os Pendrlkx1, !aap lransen1, Alessandro 1onlolo2 and leL L.C.M. van 8lel1, 18adboud unlverslLy nl[megen Medlcal CenLre, nl[megen, neLherlands, 2zer harmaceuucals, 8ome, lLaly3:00 ru2664. Lva|uanon of Csteoporos|s Med|canon Starts |n anents 8ased on 1-Score and IkAk Abso|ute Iracture k|sk Mode| |n a Large nea|th Care System8oberL A. Cverman and Chad L. ueal, Cleveland Cllnlc, Cleveland, CP3:13 ru266S. Lmc|ency Ga|ns for kheumato|ogy Consu|tanon Irom an L|ectron|c keferra| System |n a Safety Net nea|th SystemMeghan M. Schelbe1, !ohn 8. lmboden2, Cabrlela Schma[uk2, Mary Margareuen2, !onaLhan u. Craf2, Allce Chen2, Ldward P. 0*&$#2 and !lnoos ?azdany2, 1Callfornla aclc Medlcal CenLer, San lranclsco, CA, 2unlverslLy of Callfornla, San lranclsco, San lranclsco, CA3:30 ru2666. Imp|emennng a ersona||zed nea|th |an to Improve 1herapeunc Cutcomes |n Veterans W|th GoutAsLrud Lorralne Leyva1, una L. Makrls2 and Salahuddln kazl1, 1u1 SouLhwesLern Medlcal CenLer, uallas, 1x, 2u1 SouLhwesLern Medlcal CenLer, vA Medlcal CenLer, uallas, 1x3:43 ru2667. Iast-1rack athway |n G|ant Ce|| Arter|ns: A Cost-Lecnvenss Ana|ys|skaLerlna Achllleos1, ravln aul1, Wln Wln Maw1, Laura 8own2, uavld Palsall2, Charles uobson2, Chrlsuan ue[aco1, lrances 8org1, Sunll CupLa3 and 8haskar uasgupLa1, 1SouLhend unlverslLy PosplLal, WesLcll-on-sea, unlLed klngdom, 2nauonal PealLh Servlce Lngland, Leeds, unlLed klngdom, 3Cllnlcal Commlsslonlng Croup, SouLhend-on-sea, unlLed klngdom 306 ACsteoarthr|ns I: 1herapeuncs |n Csteoarthr|nsModeraLors: 1uhlna neogl, Mu, hu and Marun Lnglund, Mu, hu 2:30 ru2668. A kandom|zed, Doub|e-8||nd, Dose kang|ng Study Compar|ng Ik006, an Intra-Arncu|ar (IA) Susta|ned-ke|ease Iormu|anon of 1r|amc|no|one Aceton|de (1CA), to an Approved In[ectab|e Suspens|on of 1CA |n anents W|th Csteoarthr|ns (CA) of the kneenell 8odlck1, !oelle Luln1, Chrlsuna WlllwerLh1, lerre Lachance2, Cregory !asey3, Anll CupLa4, AnLhony Chrls3, Marc 8usso6, Mlchael C'Mahony7, Sam Peneln8, Loulse Murdoch9, lerdlnandus de Looze10, uavld PunLer11 and Mlchael Clayman1, 1llexlon 1herapeuucs, 8urllngLon, MA, 2Cllnlque SL-Louls (8echerche) lnc, Cuebec, CC, 3norLh Walkervllle CrLhopaedlc AssoclaLes, Wlndsor, Cn, 4Anll k. CupLa Medlclne rofesslonal Corporauon, 1oronLo, Cn, 3Alm PealLh Croup, WaLerloo, Cn, 6PunLer Cllnlcal 8esearch, 8roadmeadow, AusLralla, 7London 8oad ulagnosuc Cllnlc and Medlcal CenLre, Sarnla, Cn, 8SkuS 8esearch lnc., newmarkeL, Cn, 9LmerlLus 8esearch, Malvern LasL, AusLralla, 10Aus1rlals Ly LlmlLed, Sherwood, AusLralla, 118oyal norLh Shore PosplLal, SL. Leonards, AusLralla2:43 ru2669. 1reatment of knee Csteoarthr|ns anents W|th Stronnum kane|ate keduces the Loss of Carn|age Vo|ume and 8one Marrow Les|ons as Assessed 8y Magnenc kesonance Imag|ng: Data Irom the hase III Stronnum kane|ate Lmcacy |n knee Csteoarthrns 1r|a|!ohanne MarLel-elleuer1, Camllle 8oubllle1, !ean-lerre 8aynauld1, lranols Abram2, Marc uorals3, hlllppe uelorme1 and !ean-lerre elleuer1, 1CsLeoarLhrlus 8esearch unlL, unlverslLy of MonLreal PosplLal 8esearch CenLre (C8CPuM), MonLreal, CC, 2lmaglng 8esearch & uevelopmenL, ArLhroLab lnc., MonLreal, CC, 3SLaLSclences lnc., noLre-uame de l'lle erroL, CC1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 118- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo3:00 ru2670. Does Change |n Iemoronb|a| Carn|age 1h|ckness D|er 8etween Acute|y Anter|or-Cruc|ate L|gament In[ured knees 1reated W|th and W|thout keconstrucnve SurgeryWolfgang WlrLh1, lellx LcksLeln1, Marun Pudelmaler1, SLefan Lohmander2 and 8lchard lrobell3, 1aracelsus Medlcal unlverslLy, Salzburg, AusLrla, 2ueparLmenL of CrLhopedlcs, Cllnlcal Sclences Lund, Lund unlverslLy, Lund, Sweden, 3Lund unlverslLy, Lund, Sweden3:13 ru2671. 1he ke|anonsh|p 8etween 1oe-Cut Ang|e Dur|ng Wa|k|ng and k|sk of Med|a| knee Csteoarthr|ns Inc|dence: 1he Mu|ncenter Csteoarthr|ns Studyk. uouglas Cross1, ?uqlng Zhang2, Lmlly k. Culnn1, Mlchael C. nevlu3, nell A. Segal4, Cora L. Lewls3 and uavld 1. lelson2, 18osLon unlverslLy, 8osLon, MA, 28osLon unlverslLy School of Medlclne, 8osLon, MA, 3unlverslLy of Callfornla, San lranclsco, San lranclsco, CA, 4unlverslLy of lowa, lowa ClLy, lA, 3unlverslLy of Alabama, 8lrmlngham, 8lrmlngham, AL3:30 ru2672. Assoc|anons 8etween op||tea| Artery Wa|| 1h|ckness and knee Structure |n Adu|ts W|thout C||n|ca| knee D|sease: A rospecnve Cohort Study?uanyuan Wang1, ulaz novera1, AnlLa Wluka1, !esslca lalrley1, Craham Clles2, 8lchard C'Sulllvan3, Andrew 1elchLahl1 and llavla Clcumnl4, 1Monash unlverslLy, Melbourne, AusLralla, 2unlverslLy of Melbourne, Melbourne, AusLralla, 3LpworLh PosplLal, Melbourne, AusLralla, 4ueparLmenL of Lpldemlology and revenuve Medlclne, Monash unlverslLy, Melbourne, 3004, AusLralla3:43 ru2673. Morta||ty |n C||n|ca||y ke|evant Csteoarthr|ns and kheumato|d Arthr|ns Compared W|th the Genera| opu|anonAleksandra 1urklewlcz1, 1uhlna neogl2, Ceorge eaL3 and Marun Lnglund1, 1ueparLmenL of CrLhopedlcs, Cllnlcal Sclences Lund, Lund unlverslLy, Lund, Sweden, 28osLon unlverslLy School of Medlclne, 8osLon, MA, 38esearch lnsuLuLe for rlmary Care & PealLh Sclences, keele unlverslLy, keele, unlLed klngdom Sapph|re Aed|atr|c kheumato|ogy - C||n|ca| and 1herapeunc Aspects III: System|c Lupus Lrythematosus and Cther D|sease CutcomesModeraLors: Lmlly von Scheven, Mu and 8lcardo A. C. 8usso, Mu 2:30 ru2674. V|tam|n D Dehc|ency |s Common and Assoc|ated W|th Increased C-keacnve rote|n |n Ch||dren W|th Lupus: An Atherosc|eros|s revennon |n ed|atr|c Lupus Lrythematosus SubstudyAngela 8. 8oblnson1, vln 1angprlcha2, Lrlc ?ow3, 8euL Curlon1, Crace McComsey1 and Laura L. Schanberg4, 18alnbow 8ables and Chlldren's PosplLal / Case Medlcal CenLer, Cleveland, CP, 2Lmory unlverslLy School of Medlclne, ALlanLa, CA, 3uuke Cllnlcal 8esearch lnsuLuLe, uurham, nC, 4uuke unlverslLy Medlcal CenLer, uurham, nC2:43 ru267S. hase 2 1r|a| on 1r|ptore||n for Cvary rotecnon In Ch||dhood-Cnset System|c Lupus Lrythematosus8lna Mlna1, Andreas 8el2, Clovls A. Sllva3, aLrlcla vega lernandez4, Clorla C. Plgglns3, Llsa l. lmundo6, Marlsa S. kleln-ClLelman7, Calvln Wllllams8, Carol A. Wallace9, nadla L. Alkawa10, Shannen L. nelson11, !un ?lng12, Susan 8. 8ose13 and Permlne l. 8runner14, 1Clnclnnau Chlldren's PosplLal Medlcal CenLer/unlverslLy of Clnclnnau School of Medlclne, Clnclnnau, CP, 2Chlldren's PosplLal Los Angeles, Los Angeles, CA, 3laculdade de Medlclna da unlversldade de So aulo, Sao aulo, 8razll, 4Clnclnnau Chlldren's PosplLal Medlca CenLer, ClnClnnA1l, CP, 3nauonwlde Chlldrens Posp, Columbus, CP, 6Morgan SLanely Chlldren's PosplLal of new ?ork-resbyLerlan, Columbla unlverslLy Medlcal CenLer, new ?ork, n?, 7Chlldren's Memorlal PosplLal, Chlcago, lL, 8Medlcal College of Wlsconsln, Mllwaukee, Wl, 9Seaule Chlldrens Posp & 8esearch lnsuLuLe, Seaule, WA, 10laculdade de Medlclna, unlversldade de So aulo, So aulo, 8razll, 11Clnclnnau Chlldren's PosplLal Medlcal CenLer, Clnclnnau, CP, 12unlverslLy of Clnclnnau, Clnclnnau, CP, 13Clnclnnau Chlldren's PosplLal Medlcal CenLer, Clnclnnau, CP, 148CSC, Clnclnnau, CP3:00 ru2676. Increased u|se Wave Ve|oc|ty |n Iuven||e Id|opath|c Arthr|ns anents Compared to Contro|s Irom the Genera| opu|anonPanne A. Aulle1, Anne MarlL Selvaag1, vlbke Lllleby1, Cyvlnd Molberg1, Anders ParLmann2, Pallvard Poldaas2 and 8erlL llaLo1, 1ueparLmenL of 8heumaLology, Cslo unlverslLy PosplLal, 8lkshosplLaleL, Cslo, norway, 2ueparLmenL of nephrology (and speclallsed Lndocrlnology), Cslo unlverslLy PosplLal, 8lkshosplLaleL, Cslo, norway3:13 ru2677. D|sease rogress|on |nto Adu|thood |n anents W|th Iuven||e Id|opath|c Arthr|ns - A Long|tud|na| 30 ear Io||ow-Up StudyAnne MarlL Selvaag, Panne Aulle, vlbke Lllleby and 8erlL llaL, ueparLmenL of 8heumaLology, Cslo unlverslLy PosplLal, 8lkshosplLaleL, Cslo, norway3:30 ru2678. Med|ca||y S|gn|hcant Infecnons Are Increased |n anents W|th Iuven||e Id|opath|c Arthr|ns 1reated W|th Ltanercept. kesu|ts Irom the 8r|nsh Soc|ety for aed|atr|c and Ado|escent kheumato|ogy Ltanercept Cohort Study8ebecca uavles1, 1aunLon 8. SouLhwood2, Llanne kearsley-lleeL1, Mark LunL1, klmme L. Pyrlch3 and on 8ehalf Cf 1he 8SA8 LLanercepL CohorL SLudy1, 1ArLhrlus 8esearch uk Lpldemlology unlL, unlverslLy of ManchesLer, ManchesLer, unlLed klngdom, 2lnsuLuLe of Chlld PealLh, unlverslLy of 8lrmlngham and 8lrmlngham Chlldren's PosplLal, 8lrmlngham, unlLed klngdom, 3ArLhrlus 8esearch uk Lpldemlology unlL, ManchesLer Academlc PealLh Sclences CenLre, lnsuLuLe of lnammauon and 8epalr, 1he unlverslLy of ManchesLer, ManchesLer, unlLed klngdom1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 119 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo3:43 ru2679. Inc|dence kates of Ser|ous Infecnons and Infecnon Subtypes Among ed|atr|c System|c Lupus Lrythematosus anents Lnro||ed |n Med|ca|d, Accord|ng to Med|canon UseLlnda 1. Plrakl1, Candace P. leldman2, Mary 8eLh Son3, !esslca M. lranklln4, Mlchael A. llscher4, uanlel P. Solomon3, Seoyoung C. klm6, Wolfgang C. Wlnkelmayer7 and karen P. CosLenbader8, 18rlgham and Women's PosplLal, Parvard School of ubllc PealLh, 8osLon, MA, 2ulvlslon of 8heumaLology, lmmunology and Allergy, 8rlgham and Women's PosplLal, Parvard Medlcal School, 8osLon, MA, 3Chlldren's PosplLal 8osLon, 8osLon, MA, 4ulvlslon of harmacoepldemlology and harmacoeconomlcs, 8rlgham and Women's PosplLal, 8osLon, MA, 3Parvard Medlcal School, 8rlgham and Women's PosplLal, ulvlslon of 8heumaLology, ulvlslon of harmacoepldemlology, 8osLon, MA, 68rlgham and Women's PosplLal, 8osLon, MA, 7SLanford unlverslLy School of Medlclne, SLanford, CA, 88rlgham and Women's PosplLal, Parvard Medlcal School, 8osLon, MA33 Akheumato|d Arthr|ns - C||n|ca| Aspects IV: Comorb|d|nes |n kheumato|d Arthr|nsModeraLor): aul l. uellarlpa, Mu and LoreLo Carmona, Mu, hu 2:30 ru2680. k|sk of Subsequent Infecnon Among kheumato|d Arthr|ns anents Us|ng 8|o|og|csPulfeng ?un1, lenglong xle1, LllzabeLh S. uelzell1, Lang Chen1, Lmlly LevlLan1, !ames Lewls2, kenneLh C. Saag1, 1lmoLhy 8eukelman1, kevln L. WlnLhrop3, !ohn 8addley1, aul M. MunLner1 and !erey 8. Curus1, 1unlverslLy of Alabama aL 8lrmlngham, 8lrmlngham, AL, 2unlverslLy of ennsylvanla, hlladelphla, A, 3Cregon PealLh & Sclence unlverslLy, orLland, C82:43 ru2681. keduced Iern||ty |n Women W|th kheumato|d Arthr|ns: Inuence of D|sease Acnv|ty and Med|canon Use!enny 8rouwer, !ohanna MW Pazes, !oop SL Laven and 8adboud !LM uolhaln, Lrasmus unlverslLy Medlcal CenLer, 8ouerdam, neLherlands3:00 ru2682. Inc|dence 1rends and red|ctors of Crthoped|c Surgery |n anents W|th kheumato|d Arthr|ns - kesu|ts Irom a We|| Dehned opu|anonkorosh PekmaL1, LennarL !acobsson1, !an-ke nllsson1, Mlnna 1$&&$%1, Marun Lnglund2, lngemar l. eLersson3 and Carl 1uresson1, 1Lund unlverslLy, Malm, Sweden, 2Lund unlverslLy, Lund, Sweden, 3MusculoskeleLal Sclenes, ueparLmenL of CrLhopedlcs, Cllnlcal Sclences, Lund, Sweden3:13 ru2683. App||canon of a Mu|n-8|omarker D|sease Acnv|ty (Vectra DA) Score for Assess|ng kheumato|d Arthr|ns anents W|th I|bromya|g|a or Low C-keacnve rote|n?vonne C. Lee1, !ames Packeu2, Clalre Alexander3, Mlchelle A. lrlLs1, Chrlsune k. lannaccone1, nancy A. Shadlck1, Mlchael L. Welnblau1, Cscar Segurado3 and Lrlc P. Sasso3, 18rlgham and Women's PosplLal, 8osLon, MA, 2Packeu & AssoclaLes, lnc., San ulego, CA, 3Crescendo 8losclence lnc., SouLh San lranclsco, CA3:30 ru2684. Impact of Ann-kheumanc 1reatment on Immunogen|c|ty of andem|c n1N1 Inuenza Vacc|ne|n anents W|th Arthr|nsMellha C. kapeLanovlc1, Lars-Lrlk krlsLensen2, 1ore Saxne3, 1eodora AkLas4, Andreas Mrner4 and lerre Ceborek3, 1uepL of Cllnlcal Sclences Lund, Secuon of 8heumaLology, Lund unlverslLy, Lund, Sweden, 2ueparLmenL of Cllnlcal Sclences, Secuon of 8heymaLology, unlverslLy PosplLal of Skne, Lund, Sweden, 3Lund unlverslLy, Lund, Sweden, 4vacclnology unlL, ueparLmenL of ulagnosucs and vacclnology, Swedlsh lnsuLuLe for Communlcable ulsease ConLrol, Solna, Sweden., Solna, Sweden3:43 ru268S. Ann-epndy|arg|n|ne De|m|nase 3]4 Cross-keacnve Annbod|es Are Assoc|ated W|th kad|ograph|c Intersnna| Lung D|sease |n kheumato|d Arthr|ns, an Lect otennated 8y Smok|ng!on 1. Clles1, Lrlka uarrah2, Sonye k. uano2, Chellonda !ohnson2, lellpe Andrade3, AnLony 8osen2 and !oan M. 8aLhon4, 1Columbla unlverslLy, College of hyslclans & Surgeons, new ?ork, n?, 2!ohns Popklns unlverslLy, 8alumore, Mu, 3ulvlslon of 8heumaLology, !ohns Popklns unlverslLy School of Medlclne, 8alumore, Mu, 4Columbla unlverslLy, new ?ork, n?6 Ckheumato|d Arthr|ns 1reatment - Sma|| Mo|ecu|es, 8|o|og|cs and Gene 1herapy: Nove| 1reatment Strateg|es |n kheumato|d Arthr|ns ModeraLors: Cerd 8 8urmesLer, Mu and ArLhur kavanaugh, Mu 2:30 ru2686. Impact of Methotrexate Dose keducnon Upon In|nanon of Ada||mumab on C||n|ca| and U|trasonograph|c arameters |n anents W|th Moderate to Severe kheumato|d Arthr|nsCur[lL S. kaeley1, Amy M. LvangellsLo2, Mldorl !ane nlshlo3, Shufang Llu4 and ParLmuL kupper3, 1unlverslLy of llorlda, !acksonvllle, lL, 2ArLhrlus, 8heumauc and 8ack ulsease AssoclaLes, voorhees, n!, 3ulablo Cllnlcal 8esearch, WalnuL Creek, CA, 4Abbvle lnc., norLh Chlcago, lL, 3Abbvle ueuLschland CmbP & Co. kC, Ludwlgshafen, Cermany2:43 ru2687. Very n|gh kem|ss|on kates Are Ach|eved 8y Methotrexate and Intraarncu|ar G|ucocornco|ds Independent of Inducnon 1herapy W|th Ada||mumab, ear 2 C||n|ca| kesu|ts of an Invesngator-In|nated kandom|sed, Contro||ed C||n|ca| 1r|a| of Lar|y, kheumato|d Arthr|ns (CLkA)klm Prslev-eLersen1, MereLe L. PeLland2, eLer !unker3, !an denphanL4, 1orkell Llllngsen3, alle AhlqvlsL6, Panne M. Llndegaard7, AsLa Llnauskas8, Anneue Schlemmer9, Meue ?. uam10, lb Pansen11, 1lne Louenburger6, Aneue !rgensen10, Sophlne 8. krlnLel12, !ohnny 8aun1, Chrlsuan C. AmmlLzbll10, !ulla !ohansen12, Mlkkel CsLergaard13 and krlsuan SLengaard-edersen10, 1unlverslLy of SouLhern uenmark, CraasLen, uenmark, 2uAn8lC, CenLer for 8heumaLology and Splne ulseases, ClosLrup unlv PosplLal, ClosLrup, uenmark, 3unlverslLy of SouLhern uenmark, Cdense, uenmark, 4Copenhagen unlverslLy aL CenLoe, Pellerup, uenmark, 3Sllkeborg 8eglonal PosplLal, Sllkeborg, uenmark, 6unlverslLy of SouLhern uenmark, ve[le, uenmark, 7Cdense unlverslLy PosplLal, Cdense, uenmark, 8vendsyssel PosplLal, P[rrlng, uenmark, 9Aalborg unlverslLy 1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 120- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouooPosplLal, Aalborg, uenmark, 10Arhus unlverslLy PosplLal, Aarhus, uenmark, 11vlborg PosplLal, vlborg, uenmark, 12Copenhagen unlverslLy and ClosLrup PosplLal, Copenhagen, uenmark, 13Copenhagen unlverslLy PosplLal ClosLrup, Copenhagen, uenmark3:00 ru2688. Methotrexate Dose nas M|n|ma| Lects Cn Methotrexate-ke|ated 1ox|c|ty |n anents W|th Lar|y kheumato|d Arthr|ns 1reated |n Comb|nanon W|th Ada||mumab - kesu|ts of Concerto 1r|a|Cerd 8. 8urmesLer1, Alan !. klvlLz2, 8onald l. van vollenhoven3, SLefan llorenunus4, lyalal M. karunaraLne3, ParLmuL kupper6, Maxlme uougados7 and 8oy M. llelschmann8, 1CharlLe - unlverslLaLsmedlzln 8erlln, 8erlln, Cermany, 2AlLoona CenLer for Cllnlcal 8esearch, uuncansvllle, A, 31he karollnska lnsuLuLe, SLockholm, Sweden, 4Abbvle, 8ungls, lrance, 3Abbvle lnc., norLh Chlcago, lL, 6Abbvle ueuLschland Cm8P & Co kC, Ludwlgshafen, Cermany, 78ene uescarLes unlverslLy, arls, lrance, 8unlverslLy of 1exas SouLhwesLern Medlcal CenLer, uallas, 1x3:13 ru2689. Assess|ng Ma|ntenance of kem|ss|on Aher W|thdrawa| of Ltanercept |us Methotrexate, Methotrexate A|one, or |acebo |n Lar|y kheumato|d Arthr|ns anents Who Ach|eved kem|ss|on W|th Ltanercept and Methotrexate: 1he r|ze Studyaul Lmery1, Wolfgang Spleler2, Marla SLoplnska-olaszewska3, nlkolay l korshunov4, !ack 8ukowskl3, 8onald edersen3, 1heresa 1$&&$"%)6, SLefanle Caylord6 and 8onnle vlahos6, 1lnsuLuLe 8heumauc and MusculoskeleLal Medlclne unlverslLy of Leeds, Leeds, unlLed klngdom, 2ZelC8 CmbP ZenLrum fur lorschung, ZerbsL, Cermany, 3lamlly hyslclans SpeclallsLs Cllnlc, 1orun, oland, 4SLaLe 8udgeLary PealLhcare lnsuLuuon of ?aroslavl 8eglon, ?aroslavl, 8ussla, 3zer lnc, Collegevllle, A, 6zer lnc., Collegevllle, A3:30 ru2690. Surv|va| of the Second 8|o|og|c Aher the I|rst 1umor Necros|s Iactor A|pha Inh|b|tor's Ia||ure |n the 1reatment of kheumato|d Arthr|ns: rospecnve Cbservanona| Data from 8|orx.S| keg|stryZlga 8oLar1 and Mau[a 1omslc2, 1unlverslLy Medlcal CenLre L[ubl[ana, 1000 L[ubl[ana, Slovenla, 2unlverslLy Medlcal CenLre L[ub[ana, L[ubl[ana, Slovenla3:43 ru2691. kesu|ts of the Strass 1r|a| kegard|ng Impact of rogress|ve Spac|ng of 1nf-8|ocker In[ecnons |n kheumato|d Arthr|ns anents |n Das28 kem|ss|on: Is 1here a D|erence 8etween Drugs - Ada||mumab and Ltanercept - or 1he|r Mode of Use - Monotherapy or Comb|nanon?8runo lauLrel1, 1hao ham2, !acques Morel3, 1onl AlfalaLe4, Lmmanuelle uernls3, hlllppe Caudln6, Cllvler 8rocq7, LllsabeLh Solau-Cervals8, !ean-Marle 8erLheloL9, !ean-Charles 8alblanc10, xavler Marleue11 and llorence 1ubach12, 1arls 6 - lerre eL Marle Curle unlverslLy, A-P, 8heumaLology, lue-SalpLrlere PosplLal, - C8C-uMC 08 - LLMClS, arls, lrance, 2SalnLe MarguerlLe PosplLal, Marsellle, lrance, 3Lapeyronle PosplLal, MonLpelller, lrance, 4A-P, arls, lrance, 3Le Mans PosplLal, Le Mans, lrance, 6CPu PplLal Sud, Crenoble 1eachlng PosplLal, Lchlrolles, lrance, 7PosplLal of rlncesse Crce de Monaco, Monaco, lrance, 8unlverslLy PosplLal of oluers, oluers, lrance, 9nanLes unlverslLy PosplLal, nanLes, lrance, 10CenLre PosplLaller Ceneral de 8elforL, 8elforL, lrance, 118lcLre unlverslLy PosplLal, Le kremlln 8lceLre, lrance, 12unlverslLe arls ulderoL, arls, lrance31 CSpondy|arthropath|es and sor|anc Arthr|ns - athogenes|s, Lno|ogyModeraLors: !udlLh A. SmlLh, Mu, hu and 8lk Lorles, Mu, hu 2:30 ru2692. Lv|dence that Iat Metap|as|a |s a key Intermed|ary |n the Deve|opment of Sacro|||ac Io|nt Anky|os|s Io||ow|ng kepa|r of Lros|ons |n anents W|th Spondy|oarthr|nsWalLer . Maksymowych1, SLephanle Wlchuk1, raveena ChlowchanwlsawaklL2, 8oberL CW LamberL1 and Susanne !uhl edersen3, 1unlverslLy of AlberLa, LdmonLon, A8, 2Mahldol unlverslLy, 8angkok, 1halland, 3Copenhagen unlverslLy PosplLal aL ClosLrup, Copenhagen, uenmark2:43 ru2693. roof of Concept: Lnthes|ns and New 8one Iormanon |n Spondy|oarthr|ns Are Dr|ven 8y Mechan|ca| Stra|n and Stroma| Ce||seggy !acques1, Su[n LambrechL1, Lvellne verheugen1, Llln auwels2, Marleen verhoye3, Annemle van der Llnden3, Ceorge kolllas4, 8lk !. Lorles3 and ulrk LlewauL6, 1LaboraLory for Molecular lmmunology and lnammauon, ChenL unlverslLy, ChenL, 8elglum, 2uCC1, ChenL unlverslLy, ChenL, 8elglum, 3unlverslLy of AnLwerp, AnLwerp, 8elglum, 48lomedlcal Sclences 8esearch CenLer 'Alexander llemlng', varl, Creece, 3LaboraLory for SkeleLal uevelopmenL and !olnL ulsorders, ku Leuven, Leuven, 8elglum, 6ueparLmenL of 8heumaLology ChenL unlverslLy PosplLal, ChenL, 8elglum3:00 ru2694. nLA-827 Lxpress|on revents 1nfo-Induced Inh|b|non of 8one Iormanon |n V|tro |n IINy]1nfo-1reated Csteob|astsLva ?ang, Crace kwon, 8oberL A. ColberL and Cerllnde Layh-Schmlu, nlAMS nlP, 8eLhesda, Mu3:13 ru269S. nost Genenc 8ackground D|srupts the ke|anonsh|p 8etween M|crob|ota and Gut Mucosa| 1o|erance Lead|ng to Spondy|oarthr|ns and I|e|ns Aher a Decnn-1 1r|ggerLlnda 8ehaume1, SLanlslas MondoL2, uanlel Agulrre de Crcer2, !ared velasco1, Pelen 8enham1, Sumalra Pasnaln3, !aclyn 8owman1, Mer[a 8uuLu1, hlllp Pansbro4, Mlchael McCuckln3, Mark Morrlson2 and 8an[eny 1homas1, 1unlverslLy of Cueensland ulamanuna lnsuLuLe, 8rlsbane, AusLralla, 2CSl8C LlvesLock lndusLrles, 8rlsbane, AusLralla, 3MaLer Medlcal 8esearch lnsuLuLe, 8rlsbane, AusLralla, 4CenLer for AsLhma and 8esplraLory ulsease and PunLer Medlcal 8esearch lnsuLuLe, newcasLle, AusLralla1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 121 - Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo3:30 ru2696. Impa|red 8acter|a| C|earance and an Lxuberant Inammatory kesponse romote Ch|amyd|a-Induced keacnve Arthr|ns |n SkG M|ceALhan 8allleL1, Llnda 8ehaume2, Pelen 8enham2, Connor C'Meara3, Charles ArmlLage4, Marlna Parvle4, Ceraldlne 8rlzard3, !ared velasco2, !ohn v. lorresLer6, Marlapla uegll-Lsposu3, kenneLh 8eagley4 and 8an[eny 1homas2, 11he unlverslLy of Cueensland, 8rlsbane, AusLralla, 2unlverslLy of Cueensland ulamanuna lnsuLuLe, 8rlsbane, AusLralla, 3lnsuLuLe of PealLh & 8lomedlcal lnnovauon, 8lomedlcal Sclences, laculLy of PealLh, Cueensland unlverslLy of 1echnology, 8rlsbane, AusLralla, 4lnsuLuLe of PealLh & 8lomedlcal lnnovauon, 8rlsbane, AusLralla, 3Llons Lye lnsuLuLe, nedlands, AusLralla, 6Llons Lye lnsuLuLe, nedlands, 8ahraln3:43 ru2697. Idennhcanon of Genenc and Lp|genenc A|teranons |n Spondy|oarthr|ns1lbor A. 8auch1, 8eaLa 1rynlszewska1, Andras vlda1, 1lmea Ccsko1, Sandor SzanLo2, Polly L. 8osenzwelg3, Mauhew A. 8rown4, CeLhln 1homas3, kaLalln Mlkecz1 and 1lbor 1. ClanL1, 18ush unlverslLy Medlcal CenLer, Chlcago, lL, 2unlverslLy of uebrecen, uebrecen, Pungary, 3Cregon PealLh & Sclence unlverslLy, orLland, C8, 4unlverslLy of Cueensland ulamanuna lnsuLuLe, 8rlsbane, AusLralla, 3unlverslLy of Cueensland ulamanuna lnsuLuLe, Woolloongabba, AusLralla30 LSystem|c Lupus Lrythematosus - numan Lno|ogy and athogenes|s IIModeraLors: vasllelos C. kyuarls, Mu and Alessandra 8. ernls, Mu 2:30 ru2698. 1he 1reg]1h17 Imba|ance of anents W|th System|c Lupus Lrythematosus Were Med|ated 8y M|r-663 1hrough Down-kegu|anng 1GI-1 Secrenon of 8one Marrow-Der|ved Mesenchyma| Stem Ce||sLlngyu Ceng, xla Ll, xueblng leng and Llngyun Sun, ueparLmenL of 8heumaLology and lmmunology, Lhe AmllaLed urum 1ower PosplLal of nan[lng unlverslLy Medlcal School, nan[lng, Chlna2:43 ru2699. 1ranscr|pnon Iactor kIk1 kegu|ates 1h17 D|erennanon and Its ko|e |n the athogenes|s of System|c Lupus LrythematosusMlng Zhao, Congplng Llang, Clan 1ang, ?ang ?ang, ?lxln 1an and Clan[ln Lu, Second xlangya PosplLal, CenLral SouLh unlverslLy, Changsha, Chlna3:00 ru2700. Abnorma| M|tochondr|a| L|ectron 1ransport Cha|n Acnv|ty at Comp|ex I Is kegu|ated 8y N|tr|c Cx|de and N-Acety|cyste|ne |n Lupus LymphocytesLdward uoherLy1 and Andras erl2, 1Sun? upsLaLe, Syracuse, n?, 2Sun? upsLaLe Medlcal unlverslLy, Syracuse, n?3:13 ru2701. Sp|een 1yros|ne k|nase (Syk) kegu|ates System|c Lupus Lrythematosus 1 Ce|| S|gna||ngAlexandros . Crammaukos1, ueb[anl Chosh2 and vasllelos C. kyuarls3, 18eLh lsrael ueaconess Medlcal CenLer, Parvard Medlcal School, 8osLon, MA, 21he 8rody School of Medlclne, LasL Carollna unlverslLy, Creenvllle, nC, 38luMC, Parvard Medlcal School, 8osLon, MA3:30 ru2702. Mo|ecu|ar athogenes|s and Genencs of 1artrate-kes|stant Ac|d hosphatase Dehc|ency |n System|c Lupus Lrythematosus!le An1, 1racy A. 8rlggs2, Audrey uumax-vorzeL2, Allce Wledeman1, Laurence ChaperoL3, !oel lumas3, ?anlck !. Crow2 and kelLh 8. Llkon1, 1unlverslLy of WashlngLon, Seaule, WA, 2unlverslLy of ManchesLer, ManchesLer, unlLed klngdom, 3lmmunoblology & lmmunoLherapy of Cancers, La 1ronche, lrance3:43 ru2703. An Intron|c 4?B o|ymorph|sm Assoc|ated W|th System|c Lupus Lrythematosus A|ters C1CI 8|nd|ng and Ck1 Lxpress|on!lan Zhao1, 8rendan M. Clles2, 8honda L. 1aylor3, Cabrlel A. ?eue2, kara M. Lough2, Lawrence !. Abraham3, Pul Wu1, aLrlck M. Caney4, !ennlfer A. kelly4, kenneLh M. kaufman3, !ohn 8. Parley6, Carl u. Langefeld7, LllzabeLh L. 8rown8, !erey C. Ldberg9, 8oberL . klmberly8, uanlela ulglau3, 8euy . 1sao1 and Susan A. 8oackle2, 1uavld Ceen School of Medlclne unlverslLy of Callfornla Los Angeles, Los Angeles, CA, 2unlverslLy of Colorado School of Medlclne, Aurora, CC, 3unlverslLy of WesLern AusLralla, erLh, WesLern AusLralla, AusLralla, 4Cklahoma Medlcal 8esearch loundauon, Cklahoma ClLy, Ck, 3Clnclnnau Chlldren's PosplLal Medlcal CenLer and Lhe unlverslLy of Clnclnnau, Clnclnnau, CP, 6Clnclnnau Chlldren's PosplLal Medlcal CenLer, Clnclnnau, CP, 7Wake loresL School of Medlclne, WlnsLon-Salem, nC, 8unlverslLy of Alabama aL 8lrmlngham, 8lrmlngham, AL, 9ueparLmenL of Medlclne, unlverslLy of Alabama aL 8lrmlngham, 8lrmlngham, AL32 ASystem|c Sc|eros|s, I|bros|ng Syndromes, and kaynaud's II: athogenes|s, An|ma| Mode|s, Genencs: Nove| S|gna||ng athways Med|anng I|bros|sModeraLor): Serglo A. !lmenez, Mu and Marla 1ro[anowska, Mu2:30 ru2704. 1w|st1 kegu|ates 1ransform|ng Growth Iactor 8eta Dependent Acnvanon of I|brob|asts |n I|bros|skaLrln alumbo-Zerr1, Andrea Llebl1, awel Zerr1, Mlchal 1omclk2, Alya ulsLler1, Chrlsuan 8eyer1, Cllver ulsLler3, Ceorg Scheu4 and !oerg P. W. ulsLler1, 1ueparLmenL of lnLernal Medlclne lll and lnsuLuLe for Cllnlcal lmmunology, unlverslLy of Lrlangen-nuremberg, Lrlangen, Cermany, 2lnsuLuLe of 8heumaLology, ueparLmenL of 8heumaLology, 1sL laculLy of Medlclne, Charles unlverslLy, rague, Czech 8epubllc, 3ueparLmenL of 8heumaLology, unlverslLy PosplLal Zurlch, Zurlch, SwlLzerland, 4unlverslLy of Lrlangen-nuremberg, Lrlangen, Cermany1ULSDAOCTOBER 29, 2013!"#$ &'()'*+ ,((- 122- Jeootes nlltoo 5oo uleqo 8oyftoot toom locouoo2:43 ru270S. Inh|b|non of M|crorna-1SS Ame||orated Lxper|menta| I|bros|s 8y Suppress|ng Wnt and Akt athwaysClngran ?an1, Clong lu1, !le Chen1, xlnfang Puang1, nan Shen2 and Chunde 8ao1, 18en[l PosplLal, Shanghal !laoLong unlverslLy School of Medlclne, Shanghal, Chlna, 2Shanghal lnsuLuLe of 8heumaLology, 8en[l PosplLal, Shanghal !laoLong unlverslLy School of Medlclne, Shanghal, Chlna3:00 ru2706. I||1 nap|o|nsumc|ency Lxacerbates Derma| I|bros|s V|a Acnvanon of I|brob|asts, Lndothe||a| Ce||s and Macrophages |n 8|eomyc|n-1reated M|ce1akashl 1anlguchl1, ?oshlhlde Asano1, kaname AkamaLa1, Shln[l noda1, 1akehlro 1akahashl1, ?ohel lchlmura1, 1eLsuo 1oyama1, Marla 1ro[anowska2 and Shlnlchl SaLo1, 1unlverslLy of 1okyo CraduaLe School of Medlclne, 1okyo, !apan, 28osLon unlverslLy, 8osLon, MA3:13 ru2707. Downregu|anon Cf kLIS and I||1 Cooperanve|y Contr|bute to D|snnct Man|festanons of System|c Sc|eros|s In V|tro and In V|voShln[l noda1, ?oshlhlde Asano1, kaLsuhlLo lu[lu1, lchlro Manabe1, 8yozo nagal1, kaname AkamaLa1, 1akashl 1anlguchl1,